Skip to main navigation Skip to main content

CMH : Clinical and Molecular Hepatology

OPEN ACCESS
Search
Advanced Search
ABOUT
BROWSE ARTICLES
FOR CONTRIBUTORS

Page Path

20
results for

"Young Eun Chon"

Article category

Keywords

More +

Publication year

More +

"Young Eun Chon"

CMH Bulletin

The Liver Week 2025 Highlights: Celebrating the 30th Anniversary of the Korean Association for the Study of the Liver
Young Eun Chon, Ju Hyun Shim, Joo Hyun Oh, Jiwon Yang, Hyunjae Shin, Wonseok Kang, Yeongseok Hwang, Su Jong Yu, Jongman Kim, Hae Won Lee, Yoon Jun Kim, Sook-Hyang Jeong
Clin Mol Hepatol 2025;31(4):1107-1114.
Published online October 1, 2025
DOI: https://doi.org/10.3350/cmh.2025.1062
  • 1,082 View
  • 41 Download

Correspondences

Hepatic neoplasm

Correspondence to letter to the editor on “Sorafenib vs. lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: a real-world study”
Young Eun Chon, Dong Yun Kim, Hong Jae Chon, Do Young Kim
Clin Mol Hepatol 2025;31(1):e98-e100.
Published online October 21, 2024
DOI: https://doi.org/10.3350/cmh.2024.0916
  • 3,448 View
  • 57 Download
  • 1 Web of Science

Liver fibrosis, cirrhosis, and portal hypertension

Correspondence to editorial on “Optimal cut-offs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis”
Young Eun Chon, Jung Hwan Yu, Seung Up Kim
Clin Mol Hepatol 2025;31(1):e61-e63.
Published online October 15, 2024
DOI: https://doi.org/10.3350/cmh.2024.0878
  • 4,546 View
  • 39 Download

Original Articles

Autoimmune liver disease

Diagnostic accuracy of vibration-controlled transient elastography for staging liver fibrosis in autoimmune liver diseases: A systematic review and meta-analysis
Jihyun An, Young Eun Chon, Gunho Kim, Mi Na Kim, Hee Yeon Kim, Han Ah Lee, Jung Hwan Yu, Miyoung Choi, Dae Won Jun, Seung Up Kim, Ji Won Han, Young-Joo Jin
Clin Mol Hepatol 2024;30(Suppl):S134-S146.
Published online August 21, 2024
DOI: https://doi.org/10.3350/cmh.2024.0586
Background/Aims
The assessment of liver fibrosis is crucial for managing autoimmune liver diseases such as primary biliary cholangitis (PBC), autoimmune hepatitis (AIH), and primary sclerosing cholangitis (PSC). However, data on the efficacy of noninvasive tests for these diseases are limited. This meta-analysis evaluated the diagnostic accuracy of vibration-controlled transient elastography (VCTE) for staging fibrosis in patients with autoimmune liver disease.
Methods
Searches were conducted in PubMed, Embase, CINAHL, Web of Science, and Cochrane Library databases to assess the diagnostic accuracy of VCTE against histology as the reference standard in adult patients with autoimmune liver disease. The summary area under the curve (sAUC) and diagnostic odds ratio were calculated for significant fibrosis (SF), advanced fibrosis (AF), and cirrhosis, according to liver biopsy.
Results
Fourteen articles were included, comprising 559 PBC patients from six studies, 388 AIH patients from five studies, and 151 PSC patients from three studies. VCTE demonstrated good performance for fibrosis staging in PBC, AIH, and PSC. In PBC, sAUCs of VCTE were 0.87, 0.89, and 0.99 for staging SF, AF, and cirrhosis, respectively. In AIH, the sAUCs were 0.88, 0.88, and 0.92, respectively, while in PSC, they were 0.88, 0.95, and 0.92, respectively. The cutoff values for AF were 7.5–17.9 kPa in PBC, 8.18–12.1 kPa in AIH, and 9.6 kPa in PSC.
Conclusions
VCTE shows high diagnostic accuracy for staging liver fibrosis in patients with autoimmune liver diseases. This non-invasive method serves as a valuable tool for the evaluation and monitoring of fibrosis in these lifelong diseases.

Citations

Citations to this article as recorded by  Crossref logo
  • Transient elastography for assessing liver fibrosis in autoimmune liver diseases: Excellent performance but limited details: Editorial on “Diagnostic accuracy of vibration-controlled transient elastography for staging liver fibrosis in autoimmune liver di
    Kyung-Ah Kim
    Clinical and Molecular Hepatology.2025; 31(1): 275.     CrossRef
  • Diagnostic value of serum Golgi protein 73 in liver fibrosis and inflammation in patients with autoimmune hepatitis
    Yazhen Zhang, Aifang Xu, Yujiao Jin, Jing Gao, Jiahui He
    Medicine.2025; 104(26): e43064.     CrossRef
  • Targeting endoplasmic reticulum proteostasis in liver fibrosis: From signaling mechanisms to therapeutic opportunities
    Yawei Kong, Zhengyang Chen, Zhentian Nie, Wei Chen
    Pharmacological Research.2025; 217: 107823.     CrossRef
  • Diagnostic Performance of SWE and Predictive Models Based on SWE for Post-Hepatectomy Liver Failure: A Systematic Review and Meta-analysis
    Jiaxu Liang, Fukun Shi, Lan Zhang, Suo Yin, Yong Chen
    Current Medical Imaging Formerly Current Medical Imaging Reviews.2025;[Epub]     CrossRef
  • Hidden weaknesses and biological insights in machine learning models of fibrosis in autoimmune hepatitis
    Shiuan-Chih Chen, Chun-Chieh Chen
    QJM: An International Journal of Medicine.2025;[Epub]     CrossRef
  • 7,436 View
  • 165 Download
  • 6 Web of Science
  • Crossref

Steatotic liver disease

Optimal cut-offs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis
Young Eun Chon, Young-Joo Jin, Jihyun An, Hee Yeon Kim, Miyoung Choi, Dae Won Jun, Mi Na Kim, Ji Won Han, Han Ah Lee, Jung Hwan Yu, Seung Up Kim
Clin Mol Hepatol 2024;30(Suppl):S117-S133.
Published online August 21, 2024
DOI: https://doi.org/10.3350/cmh.2024.0392
Background/aims
Opinions differ regarding vibration-controlled transient elastography and magnetic resonance elastography (VCTE/MRE) cut-offs for diagnosing advanced fibrosis (AF) in patients with non-alcoholic fatty liver disease (NAFLD). We investigated the diagnostic performance and optimal cut-off values of VCTE and MRE for diagnosing AF.
Methods
Literature databases, including Medline, EMBASE, Cochrane Library, and KoreaMed, were used to identify relevant studies published up to June 13, 2023. We selected studies evaluating VCTE and MRE regarding the degree of liver fibrosis using liver biopsy as the reference. The sensitivity, specificity, and area under receiver operating characteristics curves (AUCs) of the pooled data for VCTE and MRE for each fibrosis stage and optimal cut-offs for AF were investigated.
Results
A total of 19,199 patients from 63 studies using VCTE showed diagnostic AUC of 0.83 (95% confidence interval: 0.80–0.86), 0.83 (0.80–0.86), 0.87 (0.84–0.90), and 0.94 (0.91–0.96) for ≥F1, ≥F2, ≥F3, and F4 stages, respectively. Similarly, 1,484 patients from 14 studies using MRE showed diagnostic AUC of 0.89 (0.86–0.92), 0.92 (0.89–0.94), 0.89 (0.86–0.92), and 0.94 (0.91–0.96) for ≥F1, ≥F2, ≥F3, and F4 stages, respectively. The diagnostic AUC for AF using VCTE was highest at 0.90 with a cut-off of 7.1–7.9 kPa, and that of MRE was highest at 0.94 with a cut-off of 3.62–3.8 kPa.
Conclusions
VCTE (7.1–7.9 kPa) and MRE (3.62–3.8 kPa) with the suggested cut-offs showed favorable accuracy for diagnosing AF in patients with NAFLD. This result will serve as a basis for clinical guidelines for non-invasive tests and differential diagnosis of AF.

Citations

Citations to this article as recorded by  Crossref logo
  • Correspondence to editorial on “Optimal cut-offs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: a systematic review and meta-analy
    Young Eun Chon, Jung Hwan Yu, Seung Up Kim
    Clinical and Molecular Hepatology.2025; 31(1): e61.     CrossRef
  • Essential tools for assessing advanced fibrosis in metabolic dysfunction-associated steatotic liver disease: Editorial on “Optimal cut-offs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fib
    Won Sohn
    Clinical and Molecular Hepatology.2025; 31(1): 277.     CrossRef
  • Correspondence to editorial on “Optimal cutoffs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: A systematic review and meta-analys
    Jung Hwan Yu, Seung Up Kim
    Clinical and Molecular Hepatology.2025; 31(1): e52.     CrossRef
  • Towards unification of liver stiffness measurement cutoffs: Editorial on “Optimal cut-offs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver d
    Yangyue Zhang, Vincent Wai-Sun Wong
    Clinical and Molecular Hepatology.2025; 31(1): 264.     CrossRef
  • Sustainability of General Population Screening for Steatotic Liver Disease: A Proof-of-Concept Study
    Laura De Rosa, Gabriele Ricco, Maurizia Rossana Brunetto, Ferruccio Bonino, Francesco Faita
    Healthcare.2025; 13(7): 759.     CrossRef
  • Therapeutic Efficacy of Silymarin, Vitamin E, and Essential Phospholipid Combination Therapy on Hepatic Steatosis, Fibrosis, and Metabolic Parameters in MASLD Patients: A Prospective Clinical Study
    Dan-Ionuț Gheonea, Cristina Tocia, Victor-Mihai Sacerdoțianu, Alexandra-Georgiana Bocioagă, Irina-Paula Doica, Nicolae Cătălin Manea, Adina Turcu-Știolică, Carmen-Nicoleta Oancea, Eugen Dumitru
    International Journal of Molecular Sciences.2025; 26(12): 5427.     CrossRef
  • Deep learning radiomics of elastography for diagnosing compensated advanced chronic liver disease: an international multicenter study
    Xue Lu, Haoyan Zhang, Hidekatsu Kuroda, Matteo Garcovich, Victor de Ledinghen, Ivica Grgurević, Runze Linghu, Hong Ding, Jiandong Chang, Min Wu, Cheng Feng, Xinping Ren, Changzhu Liu, Tao Song, Fankun Meng, Yao Zhang, Ye Fang, Sumei Ma, Jinfen Wang, Xiaol
    Visual Computing for Industry, Biomedicine, and Art.2025;[Epub]     CrossRef
  • Liver disease in people with latent autoimmune diabetes in adults (LADA): A cross-sectional study using magnetic resonance elastography
    Ernesto Maddaloni, Marta Zerunian, Vincenzo Cardinale, Annalisa Zurru, Rocco Amendolara, Daniela Luverà, Renata Risi, Luca D’Onofrio, Benedetta Masci, Francesco Covotta, Damiano Caruso, Domenico Alvaro, Andrea Laghi, Raffaella Buzzetti
    Diabetes Research and Clinical Practice.2025; 229: 112465.     CrossRef
  • Paired snRNA-seq and scRNA-seq analysis of MASLD patients to identify early-stage markers for disease progression
    Suebin Park, Su-Hyeon Lee, Se-eun Han, Beom Kyung Kim, Byungjin Hwang
    Hepatology Communications.2025;[Epub]     CrossRef
  • Even Lower Alcohol Intake Might Be Harmful for East Asian Males With MASLD Spectrum
    Byungyoon Yun, Juyeon Oh, Heejoo Park, Jian Lee, Beom Kyung Kim, Jin-Ha Yoon
    Clinical Gastroenterology and Hepatology.2025;[Epub]     CrossRef
  • Lean Metabolic Dysfunction‐Associated Steatotic Liver Disease: A Wolf in Sheep's Clothing
    Xixi Fang, Chenhao Xu, Jun Lu, Runzhou Zhuang, Xiao Xu, Xuyong Wei
    Cell Biochemistry and Function.2025;[Epub]     CrossRef
  • Mistakes in the utilization of vibration-controlled transient elastography in the evaluation of liver fibrosis: a narrative review
    Madunil Anuk Niriella, Uditha Bandara Dassanayake, Charith Priyanga Madurapperuma, Indeewari Prathibha Wijesingha, Arjuna Priyadarshin De Silva, Hithnadura Janaka de Silva
    Expert Review of Gastroenterology & Hepatology.2025; : 1.     CrossRef
  • 8,255 View
  • 197 Download
  • 12 Web of Science
  • Crossref

Hepatic neoplasm

Assessment of the postoperative prognosis in patients with hepatocellular carcinoma using vibration-controlled transient elastography: A systemic review and meta-analysis
Jung Hwan Yu, Ji Won Han, Young Ju Suh, Young Eun Chon, Hee Yeon Kim, Ji Hyun An, Young-Joo Jin, Miyoung Choi, Seung Up Kim, Dae Won Jun, Han Ah Lee, Mi Na Kim
Clin Mol Hepatol 2024;30(Suppl):S186-S198.
Published online August 21, 2024
DOI: https://doi.org/10.3350/cmh.2024.0366
Backgrounds/Aims
This meta-analysis examined whether preoperative vibration-controlled transient elastography (VCTE) can predict postoperative complications and recurrence in patients undergoing hepatic resection for hepatocellular carcinoma (HCC).
Methods
A systematic literature search was conducted using Ovid-Medline, EMBASE, Cochrane, and KoreaMed databases. Out of 431 individual studies, thirteen published between 2008 and 2022 were included. Five studies focused on HCC recurrence, while eight examined postoperative complications.
Results
The meta-analysis of five studies on HCC recurrence showed that the high-risk group with a high VCTE score had a significantly increased recurrence rate after hepatic resection (hazard ratio 2.14). The cutoff value of VCTE in the high-risk group of HCC recurrence was 7.4–13.4 kPa, the sensitivity was 0.60 (95% confidence interval [CI] 0.47–0.72), and the specificity was 0.60 (95% CI 0.46–0.72). The area under the receiver operating characteristic curve (AUC) of the liver stiffness measured by VCTE to predict the HCC recurrence was 0.63 (95% CI 0.59–0.67). The meta-analysis on the postoperative complications revealed a significantly increased risk of postoperative complications in the high-risk group (12–25.6 kPa) with a high VCTE value (odds ratio [OR], 8.32). The AUC of the liver stiffness measured by VCTE to predict the postoperative complications was 0.87 (95% CI 0.84–0.90), the sensitivity was 0.76 (95% CI 0.55–0.89) and the specificity was 0.85 (95% CI 0.73–0.92).
Conclusions
This meta-analysis suggests that preoperative VCTE in patients undergoing hepatic resection for HCC is useful in identifying individuals at a high risk of postoperative complications and HCC recurrence.

Citations

Citations to this article as recorded by  Crossref logo
  • Recent Trends in Noninvasive Tests for Assessing Hepatic Fibrosis in Patients with Chronic Liver Disease
    Jung Hwan Yu
    The Korean Journal of Medicine.2024; 99(5): 232.     CrossRef
  • 4,947 View
  • 109 Download
  • 1 Web of Science
  • Crossref

Special Issue

Liver fibrosis, cirrhosis, and portal hypertension

KASL clinical practice guidelines for noninvasive tests to assess liver fibrosis in chronic liver disease
Mi Na Kim, Ji Won Han, Jihyun An, Beom Kyung Kim, Young-Joo Jin, Seung-seob Kim, Minjong Lee, Han Ah Lee, Yuri Cho, Hee Yeon Kim, Yu Rim Shin, Jung Hwan Yu, Moon Young Kim, YoungRok Choi, Young Eun Chon, Eun Ju Cho, Eun Joo Lee, Sang Gyune Kim, Won Kim, Dae Won Jun, Seung Up Kim, on behalf of The Korean Association for the Study of the Liver (KASL)
Clin Mol Hepatol 2024;30(Suppl):S5-S105.
Published online August 19, 2024
DOI: https://doi.org/10.3350/cmh.2024.0506

Citations

Citations to this article as recorded by  Crossref logo
  • Correspondence to editorial on “Prevalence of clinically significant liver fibrosis in the general population: A systematic review and meta-analysis”
    Hee Yeon Kim, Miyoung Choi, Dae Won Jun
    Clinical and Molecular Hepatology.2025; 31(1): e48.     CrossRef
  • Non-Invasive Liver Fibrosis Test Using Shear Wave Elastography
    Ji Won Han
    The Korean Journal of Medicine.2025; 100(1): 26.     CrossRef
  • Influence of Sex in the Development of Liver Diseases
    Jie-Wen Zhang, Nan Zhang, Yi Lyu, Xu-Feng Zhang
    Seminars in Liver Disease.2025; 45(01): 015.     CrossRef
  • KASL clinical practice guidelines for the management of metabolic dysfunction-associated steatotic liver disease 2025
    Won Sohn, Young-Sun Lee, Soon Sun Kim, Jung Hee Kim, Young-Joo Jin, Gi-Ae Kim, Pil Soo Sung, Jeong-Ju Yoo, Young Chang, Eun Joo Lee, Hye Won Lee, Miyoung Choi, Su Jong Yu, Young Kul Jung, Byoung Kuk Jang
    Clinical and Molecular Hepatology.2025; 31(Suppl): S1.     CrossRef
  • Noninvasive identification of metabolic dysfunction–associated steatohepatitis (INFORM MASH): a retrospective cohort and disease modeling study
    G. Craig Wood, Anthony Hoovler, Rakesh Luthra, Christopher D. Still, Hamzah Shariff, Matthew Still, Jonathan Hayes, Peter Benotti, Chioma Uzoigwe
    Expert Review of Gastroenterology & Hepatology.2025; 19(4): 427.     CrossRef
  • Age serves as the silent architect of FIB-4’s precision in unveiling advanced hepatic fibrosis in MASLD with T2DM: Correspondence to letter to the editor on “Diagnostic accuracy of the fibrosis-4 index for advanced liver fibrosis in nonalcoholic fatty liv
    Ji Won Han, Dae Won Jun
    Clinical and Molecular Hepatology.2025; 31(2): e152.     CrossRef
  • The association between modified cardiometabolic index with non-alcoholic fatty liver disease and liver fibrosis: a cross-sectional study
    Yanjun Guo, Wei Su, Lulong Tao, Guoxin Zhang, Kun Wang
    BMC Gastroenterology.2025;[Epub]     CrossRef
  • Future Perspectives of Liver Research in the Asia‐Pacific Region: Focus on Hepatitis B and C
    Beom Kyung Kim
    Journal of Gastroenterology and Hepatology.2025; 40(8): 1855.     CrossRef
  • Novel Insights into Noninvasive Assessment of Liver Fibrosis in Chronic Hepatitis C Patients
    Guanlan Liu, Li Liu, Xing Yang, Qihao Wang, Mingqin Qian
    Journal of Clinical and Experimental Hepatology.2025; 15(6): 102610.     CrossRef
  • A Case Report of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) with Improved Cardiometabolic Risk Factors Following Treatment with Saenggangunbi-tang
    Eun Kyung Lee, Min Jeong Park, Youngchul Kim, Jang-Hoon Lee
    The Journal of Internal Korean Medicine.2025; 46(2): 303.     CrossRef
  • Risk stratification by noninvasive tests in patients with metabolic dysfunction-associated steatotic liver disease
    Hye Won Lee, Jae Seung Lee, Mi Na Kim, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim
    Clinical and Molecular Hepatology.2025; 31(3): 1018.     CrossRef
  • Performance of APRI and FIB-4 Scores Compared to FibroScan: A Cross-Sectional Study in a Black Sub-Saharan African Population
    Jean-Bonny Nsumbu, Jean-Robert Makulo, Trésor Mutombo Tshiswaka, Christian Kisoka Lusunsi, Charles Nlombi Mbendi
    Hepatic Medicine: Evidence and Research.2025; Volume 17: 27.     CrossRef
  • Correspondence to editorial 1 on “Baveno VI-SSM stratifies the risk of portal hypertension-related events in patients with HBV-related cirrhosis”
    Haiyu Wang, Jinjun Chen
    Clinical and Molecular Hepatology.2025;[Epub]     CrossRef
  • Quantification of liver steatosis of metabolic dysfunction-associated steatotic liver disease based on body composition analysis
    Toshikazu Kohira, Satoshi Oeda, Erina Eto, Yoshihito Kubotsu, Misa Norita, Kaori Inoue, Nagisa Hara, Shotaro Noge, Kenichi Tanaka, Shigenobu Yoshimura, Noriko Oza, Keizo Anzai, Yuichiro Eguchi, Cheng Han Ng, Daniel Q. Huang, Mark D. Muthiah, Atsushi Kawag
    Scientific Reports.2025;[Epub]     CrossRef
  • Longitudinal Effects of Glecaprevir/Pibrentasvir on Liver Function, Fibrosis, and Hepatocellular Carcinoma Risk in Chronic Hepatitis C: A Prospective Multicenter Cohort Study
    Jung Hee Kim, Jae Hyun Yoon, Sung-Eun Kim, Ji-Won Park, Yewan Park, Gi-Ae Kim, Seong Kyun Na, Young-Sun Lee, Jeong Han Kim
    Medicina.2025; 61(9): 1601.     CrossRef
  • Comment on ‘Association Between Handgrip Strength and Cardiovascular Disease Risk in MASLD: A Prospective Study From UK Biobank’ by T. S. Lim et al.—Authors' Reply
    Tae Seop Lim, Sujin Kwon, Sung A Bae, Hye Yeon Chon, Seol A. Jang, Ja Kyung Kim, Chul Sik Kim, Seok Won Park, Kyoung Min Kim
    Journal of Cachexia, Sarcopenia and Muscle.2025;[Epub]     CrossRef
  • Aspirin Use and Risk of HCC and Gastrointestinal Bleeding in Patients With HBV‐Related Cirrhosis: A Landmark Analysis
    Mi Na Kim, Geun U. Park, Seng Chan You, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn
    Journal of Gastroenterology and Hepatology.2025; 40(11): 2750.     CrossRef
  • Prospects of late-stage development agents in the treatment of metabolic dysfunction-associated steatohepatitis
    Brian Lee, Ussama Ghumman, Lisa D. Pedicone, Andres Gomez Aldana, Eric Lawitz
    Clinical and Molecular Hepatology.2025; 31(4): 1167.     CrossRef
  • Discovery of ultrasound-derived fat fraction as a non-invasive tool for MASLD diagnosis
    Huiru Jin, Mengfan Jiao, Chengxiao Yu, Tingting Ren, Qingling Chen, Zixing Dai, Erfu Xie, Longfeng Jiang, Yuwen Li
    European Journal of Medical Research.2025;[Epub]     CrossRef
  • Mistakes in the utilization of vibration-controlled transient elastography in the evaluation of liver fibrosis: a narrative review
    Madunil Anuk Niriella, Uditha Bandara Dassanayake, Charith Priyanga Madurapperuma, Indeewari Prathibha Wijesingha, Arjuna Priyadarshin De Silva, Hithnadura Janaka de Silva
    Expert Review of Gastroenterology & Hepatology.2025; : 1.     CrossRef
  • Enhanced Prediction of Hepatitis B Virus-Related Hepatocellular Carcinoma Using Age-male-albumin-bilirubin-platelet (aMAP) and Liver Stiffness Assessed by Vibration-controlled Transient Elastography
    Hye Yeon Chon, Hyung Joon Yim, Seok-Jae Heo, Su Jong Yu, Ja Kyung Kim, Sang Hoon Ahn, Grace Lai-Hung Wong, Jimmy Che-To Lai, Terry Cheuk-Fung Yip, Sang Gyune Kim, Yeon Seok Seo, Seung Up Kim
    Clinical Gastroenterology and Hepatology.2025;[Epub]     CrossRef
  • Recent Trends in Noninvasive Tests for Assessing Hepatic Fibrosis in Patients with Chronic Liver Disease
    Jung Hwan Yu
    The Korean Journal of Medicine.2024; 99(5): 232.     CrossRef
  • Noninvasive Imaging Test to Assess Liver Fibrosis: Vibration-controlled Transient Elastography
    Mi Na Kim
    The Korean Journal of Gastroenterology.2024; 84(5): 201.     CrossRef
  • Non-Invasive Test for Assessment of Liver Fibrosis in Chronic Hepatitis B
    Ye Ji Jun, Minjong Lee, Ho Soo Chun, Tae Hun Kim
    The Korean Journal of Gastroenterology.2024; 84(5): 206.     CrossRef
  • Serological Markers to Assess Liver Fibrosis and Their Roles
    Beom Kyung Kim
    The Korean Journal of Gastroenterology.2024; 84(5): 195.     CrossRef
  • Liver Fibrosis Assessment in Chronic Liver Diseases Using Elastography: A Comprehensive Review of Vibration-Controlled Transient Elastography and Shear Wave Elastography
    Han Ah Lee
    Clinical Ultrasound.2024; 9(2): 70.     CrossRef
  • 12,786 View
  • 301 Download
  • 24 Web of Science
  • Crossref

Original Articles

Hepatic neoplasm

Non-invasive prediction of post-sustained virological response hepatocellular carcinoma in hepatitis C virus: A systematic review and meta-analysis
Han Ah Lee, Mi Na Kim, Hye Ah Lee, Miyoung Choi, Jung Hwan Yu, Young-Joo Jin, Hee Yeon Kim, Ji Won Han, Seung Up Kim, Jihyun An, Young Eun Chon
Clin Mol Hepatol 2024;30(Suppl):S172-S185.
Published online August 12, 2024
DOI: https://doi.org/10.3350/cmh.2024.0262
Backgrounds/Aims
Despite advances in antiviral therapy for hepatitis C virus (HCV) infection, hepatocellular carcinoma (HCC) still develops even after sustained viral response (SVR) in patients with advanced liver fibrosis or cirrhosis. This meta-analysis investigated the predictive performance of vibration-controlled transient elastography (VCTE) and fibrosis 4-index (FIB-4) for the development of HCC after SVR.
Methods
We searched PubMed, MEDLINE, EMBASE, and the Cochrane Library for studies examining the predictive performance of these tests in adult patients with HCV. Two authors independently screened the studies’ methodological quality and extracted data. Pooled estimates of sensitivity, specificity, and area under the curve (AUC) were calculated for HCC development using random-effects bivariate logit normal and linear-mixed effect models.
Results
We included 27 studies (169,911 patients). Meta-analysis of HCC after SVR was possible in nine VCTE and 15 FIB-4 studies. Regarding the prediction of HCC development after SVR, the pooled AUCs of pre-treatment VCTE >9.2–13 kPa and FIB-4 >3.25 were 0.79 and 0.73, respectively. VCTE >8.4–11 kPa and FIB-4 >3.25 measured after SVR maintained good predictive performance, albeit slightly reduced (pooled AUCs: 0.77 and 0.70, respectively). The identified optimal cut-off value for HCC development after SVR was 12.6 kPa for pre-treatment VCTE. That of VCTE measured after the SVR was 11.2 kPa.
Conclusions
VCTE and FIB-4 showed acceptable predictive performance for HCC development in patients with HCV who achieved SVR, underscoring their utility in clinical practice for guiding surveillance strategies. Future studies are needed to validate these findings prospectively and validate their clinical impact.

Citations

Citations to this article as recorded by  Crossref logo
  • Comment: Non-invasive prediction of post-sustained virological response hepatocellular carcinoma in hepatitis C virus
    Xinpu Miao, Haidong Wu, Jinrong Xu, Wei Cheng
    Clinical and Molecular Hepatology.2025; 31(1): e23.     CrossRef
  • Hepatocellular carcinoma surveillance after sustained virological response in chronic hepatitis C: Editorial on “Non-invasive prediction of post-sustained virological response hepatocellular carcinoma in hepatitis C virus: A systematic review and meta-ana
    Ho Soo Chun, Minjong Lee
    Clinical and Molecular Hepatology.2025; 31(1): 261.     CrossRef
  • Longitudinal Effects of Glecaprevir/Pibrentasvir on Liver Function, Fibrosis, and Hepatocellular Carcinoma Risk in Chronic Hepatitis C: A Prospective Multicenter Cohort Study
    Jung Hee Kim, Jae Hyun Yoon, Sung-Eun Kim, Ji-Won Park, Yewan Park, Gi-Ae Kim, Seong Kyun Na, Young-Sun Lee, Jeong Han Kim
    Medicina.2025; 61(9): 1601.     CrossRef
  • Precision Strategy for Hepatocellular Carcinoma Surveillance after Hepatitis C Cure: Debates across Guidelines
    Masaaki Mino, Eiji Kakazu, Tatsuya Kanto
    Gut and Liver.2025; 19(5): 651.     CrossRef
  • Liver Stiffness Measurements After Oral Antivirals Effectively Predict the Risk of HCC in Patients With Chronic Hepatitis C
    Yu Rim Lee, Hyun Young Woo, Young Oh. Kweon, Won Young Tak, Se Young Jang, Jung Gil Park, Min Kyu Kang, Jeong Eun Song, Byoung Kuk Jang, Changhyeong Lee, Byung Seok Kim, Jae Seok Hwang, Woo Jin Chung, Jeong Heo, Nae‐Yun Heo, Seung Ha Park, Jun Sik Yoon, J
    Journal of Gastroenterology and Hepatology.2025; 40(10): 2568.     CrossRef
  • Diagnostic possibilities of perfusion computed tomography in assessing fibrosis regression in patients with chronic viral hepatitis C: a prospective study
    E. A. Ioppa, O. S. Tonkikh, I. Yu. Degtyarev, V. D. Zavadovskaya, E. S. Garganeeva
    Diagnostic radiology and radiotherapy.2025; 16(3): 65.     CrossRef
  • Liver Fibrosis Assessment in Chronic Liver Diseases Using Elastography: A Comprehensive Review of Vibration-Controlled Transient Elastography and Shear Wave Elastography
    Han Ah Lee
    Clinical Ultrasound.2024; 9(2): 70.     CrossRef
  • 6,216 View
  • 164 Download
  • 4 Web of Science
  • Crossref

Liver fibrosis, cirrhosis, and portal hypertension

Prevalence of clinically significant liver fibrosis in the general population: A systematic review and meta-analysis
Hee Yeon Kim, Jung Hwan Yu, Young Eun Chon, Seung Up Kim, Mi Na Kim, Ji Won Han, Han Ah Lee, Young-Joo Jin, Jihyun An, Miyoung Choi, Dae Won Jun
Clin Mol Hepatol 2024;30(Suppl):S199-S213.
Published online July 30, 2024
DOI: https://doi.org/10.3350/cmh.2024.0351
Background/Aims
Although important, clinically significant liver fibrosis is often overlooked in the general population. We aimed to examine the prevalence of clinically significant liver fibrosis using noninvasive tests (NITs) in the general population.
Methods
We collected data from four databases (MEDLINE, Embase, Cochrane Library, and KoreaMed) from inception to June 13, 2023. Original articles reporting the prevalence of clinically significant liver fibrosis in the general population were included. The Stata metaprop function was used to obtain the pooled prevalence of liver fibrosis with NITs in the general population.
Results
We screened 6,429 articles and included 45 eligible studies that reported the prevalence of clinically significant liver fibrosis in the general population. The prevalence of advanced liver fibrosis, using the high probability cutoff of the fibrosis-4 (FIB-4) index, was 2.3% (95% confidence interval [CI], 1.2–3.7%). The prevalence of significant liver fibrosis, advanced liver fibrosis, and liver cirrhosis, assessed using vibration-controlled transient elastography (VCTE) among the general population, was 7.3% (95% CI, 5.9–8.8%), 3.5% (95% CI, 2.7–4.5), and 1.2% (95% CI, 0.8–1.8%), respectively. Region-based subgroup analysis revealed that the highest prevalence of advanced fibrosis using the high probability cutoff of the FIB-4 index was observed in the American region. Furthermore, the American region exhibited the highest prevalence of significant liver fibrosis, advanced liver fibrosis, and liver cirrhosis, using VCTE.
Conclusions
Previously undiagnosed clinically significant liver fibrosis is found in the general population through NITs. Future research is necessary to stratify the risk in the general population.

Citations

Citations to this article as recorded by  Crossref logo
  • Spotting undiagnosed significant liver fibrosis in the general population: impact on subsequent clinical care: Editorial on “Prevalence of clinically significant liver fibrosis in the general population: A systematic review and meta-analysis”
    Nana Peng, Mary Yue Wang, Sherlot Juan Song, Terry Cheuk-Fung Yip
    Clinical and Molecular Hepatology.2025; 31(1): 256.     CrossRef
  • Correspondence to editorial on “Prevalence of clinically significant liver fibrosis in the general population: A systematic review and meta-analysis”
    Hee Yeon Kim, Miyoung Choi, Dae Won Jun
    Clinical and Molecular Hepatology.2025; 31(1): e48.     CrossRef
  • Letter regarding “Prevalence of clinically significant liver fibrosis in the general population”
    Wei Feng, Qile Wang, Qingwang Ye
    Clinical and Molecular Hepatology.2025; 31(1): e21.     CrossRef
  • Correspondence to letter to the editor on “Prevalence of clinically significant liver fibrosis in the general population: A systematic review and meta-analysis”
    Hee Yeon Kim, Miyoung Choi, Dae Won Jun
    Clinical and Molecular Hepatology.2025; 31(1): e105.     CrossRef
  • Hypoxia-inducible factor-1 alpha (HIF-1α) inhibitor AMSP-30 m attenuates CCl4-induced liver fibrosis in mice by inhibiting the sonic hedgehog pathway
    Lili Lu, Yuchen Ma, Qing Tao, Jing Xie, Xiao Liu, Yongkang Wu, Yang Zhang, Xiuli Xie, Mingming Liu, Yong Jin
    Chemico-Biological Interactions.2025; 413: 111480.     CrossRef
  • Vibration-controlled transient elastography in shaping the epidemiology and management of steatotic liver disease: Editorial on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017–2023”
    Xiao-Dong Zhou, Terry Cheuk-Fung Yip, Daniel Q Huang, Mark Dhinesh Muthiah, Mazen Noureddin, Ming-Hua Zheng
    Clinical and Molecular Hepatology.2025; 31(2): 620.     CrossRef
  • Simple Clinical Prediction Rules for Identifying Significant Liver Fibrosis: Evaluation of Established Scores and Development of the Aspartate Aminotransferase-Thrombocytopenia-Albumin (ATA) Score
    Puwitch Charoenchue, Jiraporn Khorana, Apichat Tantraworasin, Suwalee Pojchamarnwiputh, Wittanee Na Chiangmai, Amonlaya Amantakul, Taned Chitapanarux, Nakarin Inmutto
    Diagnostics.2025; 15(9): 1119.     CrossRef
  • Targeting endoplasmic reticulum proteostasis in liver fibrosis: From signaling mechanisms to therapeutic opportunities
    Yawei Kong, Zhengyang Chen, Zhentian Nie, Wei Chen
    Pharmacological Research.2025; 217: 107823.     CrossRef
  • Decoding the hepatic fibrosis-hepatocellular carcinoma axis: from mechanisms to therapeutic opportunities
    Anqi Lin, Minying Xiong, Bufu Tang, Aimin Jiang, Junyi Shen, Zaoqu Liu, Quan Cheng, Jian Zhang, Peng Luo
    Hepatology International.2025; 19(4): 732.     CrossRef
  • Cost-effectiveness of advanced hepatic fibrosis screening in individuals with suspected MASLD identified by serologic noninvasive tests
    Huiyul Park, Eileen L. Yoon, Mimi Kim, Ji-hyeon Park, Ramsey Cheung, Jeong-Yeon Cho, Hye-Lin Kim, Dae Won Jun
    Scientific Reports.2025;[Epub]     CrossRef
  • Senkyunolide I targets CXCR4 to attenuate liver fibrosis via suppression of the NLRP3/GSDMD pathway
    Kexin Wang, Yuxin Yang, Bingjie Yue, Mengyang Li, Chu Chen, Junrong Du, Fangyi Long
    International Immunopharmacology.2025; 164: 115348.     CrossRef
  • Chronic liver disease and radiation-induced second primary liver malignancy: a retrospective cohort based on SEER database 2010–2021
    Asmaa Ellaithy, Aya Serageldeen, Alhareth Alhusban, Mariam Emad Seif, Mahmoud Essam Abdelhamid, Bushra Al-Shaikh, Asmaa Sayed Ibrahim, Eslam Mohamed Elshennawy, Ibrahim Ellaithy
    Annals of Medicine & Surgery.2025; 87(8): 4742.     CrossRef
  • PREVALENCE OF VARIOUS ETIOPATHOGENIC VARIANTS OF CHRONIC DIFFUSE LIVER DISEASES
    B. Sakhova, A. Oshibayeva, N. Nuskabayeva, E. Iskandirova, Zh. Rsalieva, N. Karabayev, L. Karimova, L. Ozbakyr
    Medicine and ecology.2025; (3): 35.     CrossRef
  • Association between gestational diabetes mellitus and liver cirrhosis and fibrosis: A population‐based cohort study and risk factor analysis
    Tan‐Tzu Lo, Wan‐Ting Huang, Chia‐Lung Shih, Pensee Wu
    International Journal of Gynecology & Obstetrics.2025;[Epub]     CrossRef
  • Modified FIB-4 Index in Type 2 Diabetes Mellitus with Steatosis: A Non-Linear Predictive Model for Advanced Hepatic Fibrosis
    Jonghyun Kim, Takanori Ito, Taeang Arai, Masanori Atsukawa, Miwa Kawanaka, Hidenori Toyoda, Takashi Honda, Ming-Lung Yu, Eileen L. Yoon, Dae Won Jun, Kyungjoon Cha, Mindie H. Nguyen
    Diagnostics.2024; 14(22): 2500.     CrossRef
  • 10,218 View
  • 200 Download
  • 15 Web of Science
  • Crossref

Steatotic liver disease

Diagnostic accuracy of the Fibrosis-4 index for advanced liver fibrosis in nonalcoholic fatty liver disease with type 2 diabetes: A systematic review and meta-analysis
Ji Won Han, Hee Yeon Kim, Jung Hwan Yu, Mi Na Kim, Young Eun Chon, Ji Hyun An, Young-Joo Jin, Miyoung Choi, Seung Up Kim, Han Ah Lee, Dae Won Jun
Clin Mol Hepatol 2024;30(Suppl):S147-S158.
Published online July 25, 2024
DOI: https://doi.org/10.3350/cmh.2024.0330
Background/Aims
The Fibrosis-4 index (FIB-4) is a noninvasive test widely used to rule out advanced liver fibrosis (AF) in patients with nonalcoholic fatty liver disease (NAFLD). However, its diagnostic accuracy in NAFLD patients with type 2 diabetes mellitus (T2DM) is controversial due to the high prevalence of AF in this population.
Methods
Research focusing on the diagnostic accuracy of FIB-4 for liver fibrosis as validated by liver histology in NAFLD patients with T2DM was included, and 12 studies (n=5,624) were finally included in the meta-analysis. Sensitivity, specificity, hierarchical summary receiver operating characteristic (HSROC), positive predictive values (PPVs), and negative predictive values (NPVs) at low cutoffs (1.3–1.67) and high cutoffs (2.67–3.25) for ruling in and out AF were calculated.
Results
At low cutoffs, the meta-analysis revealed a sensitivity of 0.74, specificity of 0.62, and HSROC of 0.75. At high cutoffs, the analysis showed a sensitivity of 0.33, specificity of 0.92, and HSROC of 0.85, suggesting FIB-4 as useful for identifying or excluding AF. In subgroup analyses, high mean age and F3 prevalence were associated with lower sensitivity. The calculated NPV and PPV were 0.82 and 0.49 at low cutoffs, whereas the NPV was 0.28 and the PPV was 0.70 at high cutoffs. There were insufficient estimated NPVs <0.90 at a hypothesized prevalence of AF >30% at an FIB-4 cutoff range of 1.3–1.67.
Conclusions
Collectively, FIB-4 has moderate diagnostic accuracy for identifying or excluding AF in NAFLD patients with T2DM, but more evidence must be accumulated due to the limited number of currently reported studies and their heterogeneity.

Citations

Citations to this article as recorded by  Crossref logo
  • Prognostic value of the FIB-4 index in patients with myocardial infarction with non-obstructive coronary arteries
    Wei Zhang, Yuqi Chen, Liu Zhu, Siliang Peng, Mengchao Jin, Jiayu Yin
    International Journal of Cardiology.2026; 445: 134045.     CrossRef
  • Reply to: “A machine learning model to predict liver-related outcomes after the functional cure of chronic hepatitis B: Is cirrhosis driving the performance?”
    Moon Haeng Hur, Jeong-Hoon Lee
    Journal of Hepatology.2025; 82(3): e143.     CrossRef
  • The fibrosis-4 index for advanced liver fibrosis in NAFLD with T2DM: Half a loaf is better than no bread
    Zeyu Wang, Dong Wan, Meidong Xu, Yong Jiang
    Clinical and Molecular Hepatology.2025; 31(1): e25.     CrossRef
  • Non-Invasive Liver Fibrosis Test Using Shear Wave Elastography
    Ji Won Han
    The Korean Journal of Medicine.2025; 100(1): 26.     CrossRef
  • Age serves as the silent architect of FIB-4’s precision in unveiling advanced hepatic fibrosis in MASLD with T2DM: Correspondence to letter to the editor on “Diagnostic accuracy of the fibrosis-4 index for advanced liver fibrosis in nonalcoholic fatty liv
    Ji Won Han, Dae Won Jun
    Clinical and Molecular Hepatology.2025; 31(2): e152.     CrossRef
  • Targeting endoplasmic reticulum proteostasis in liver fibrosis: From signaling mechanisms to therapeutic opportunities
    Yawei Kong, Zhengyang Chen, Zhentian Nie, Wei Chen
    Pharmacological Research.2025; 217: 107823.     CrossRef
  • Comparison of FIB-4, APRI and AST/ALT ratio with FibroScan in patients with NAFLD and type 2 diabetes: a single-center study from Bangladesh
    Muhammad Shah Alam, Syeda Tanzina Kalam, Monirul Islam Khan, Jabed Ahmed, Rahul Saha, A. B. M. Kamrul-Hasan
    Egyptian Liver Journal.2025;[Epub]     CrossRef
  • Part 2: CAR Metabolic Dysfunction-Associated Steatotic Liver Disease Working Group Recommendations for Risk Stratifying Patients With MASLD
    Mitchell P. Wilson, Gavin Low, Abdel-Aziz Shaheen, Andreu F. Costa, An Tang, Emily Pang, Silvia Chang, Alexandra Medellin, Jérémy Dana, Noam Millo, Ania Kielar, Li Xin Zhang, Toni Whitaker, Mark Swain, Victoria Leung, Daisy Fung, Casey Hurrell, Christophe
    Canadian Association of Radiologists Journal.2025;[Epub]     CrossRef
  • Impact of a high dietary fiber cereal meal intervention on the progression of liver fibrosis in T2DM with MASLD
    Xi-Shuang Chen, Hui-Zhen Liu, Fang Huang, Jian Meng, Jing-Xian Fang, Yu Han, Hui-Ming Zou, Qing Gu, Xue Hu, Qian-Wen Ma, Yue-Xia Han, Sui-Jun Wang
    Frontiers in Endocrinology.2025;[Epub]     CrossRef
  • Association between fibrosis-4 index and coronary heart disease: a population-based study
    Pan Jia, Mamajan Annamyradova, Genhao Fan, Qizhen Zhang, Yankun Song, Qiaozhi Li, Minghao Liu, Zuoying Xing, Yongxia Wang
    BMC Cardiovascular Disorders.2025;[Epub]     CrossRef
  • Forns index and fatty liver index, but not FIB-4, are associated with indices of glycaemia, pre-diabetes and type 2 diabetes: analysis of The Maastricht Study
    Leen Heyens, Hanna Kenjic, Pieter Dagnelie, Casper Schalkwijk, Coen Stehouwer, Steven Meex, Jeroen Kooman, Otto Bekers, Marleen van Greevenbroek, Hans Savelberg, Geert Robaeys, Bastiaan de Galan, Annemarie Koster, Martien van Dongen, Simone Eussen, Ger Ko
    BMJ Open Gastroenterology.2024; 11(1): e001466.     CrossRef
  • 5,942 View
  • 177 Download
  • 10 Web of Science
  • Crossref

Viral hepatitis

Vibration-controlled transient elastography for significant fibrosis in treatment-naïve chronic hepatitis B patients: A systematic review and meta-analysis
Mi Na Kim, Jihyun An, Eun Hwa Kim, Hee Yeon Kim, Han Ah Lee, Jung Hwan Yu, Young-Joo Jin, Young Eun Chon, Seung Up Kim, Dae Won Jun, Ji Won Han, Miyoung Choi
Clin Mol Hepatol 2024;30(Suppl):S106-S116.
Published online July 23, 2024
DOI: https://doi.org/10.3350/cmh.2024.0371
Backgrounds/Aims
Accurate diagnosis of significant liver fibrosis in patients with chronic hepatitis B (CHB) is crucial when determining whether to initiate antiviral treatment (AVT). We conduct a meta-analysis to assess the diagnostic performance of vibration-controlled transient elastography (VCTE) for significant liver fibrosis in AVT-naïve CHB patients with serum alanine transaminase (ALT) levels within 5-fold the upper limit of normal (ULN).
Methods
The Ovid-Medline, EMBASE, Cochrane, and KoreaMed databases were searched to identify studies that compared the performance of VCTE and liver biopsy (reference standard) when diagnosing significant liver fibrosis (≥F2) in AVT-naïve CHB patients with ALT within 5-fold the ULN. A hierarchical summary receiver operating characteristic curve (HSROC) and bivariate model were performed to evaluate the diagnostic performance of VCTE in the meta-analysis.
Results
Eight studies (2,003 patients) were included. The summary sensitivity and specificity for diagnosis of significant liver fibrosis were 0.78 (95% confidence interval [CI], 0.66–0.86) and 0.72 (95% CI, 0.60–0.82), respectively. The HSROC for the diagnosis of significant liver fibrosis was 0.81 (95% CI, 0.72–0.86). The optimal cutoff value of VCTE for diagnosis of significant liver fibrosis was 7.7 kPa with a sensitivity of 0.64 (95% CI, 0.50–0.76) and specificity of 0.83 (95% CI, 0.72–0.90).
Conclusions
Our study demonstrated that VCTE has an acceptable diagnostic performance for significant liver fibrosis in AVT-naïve CHB patients with ALT within 5-fold the ULN.

Citations

Citations to this article as recorded by  Crossref logo
  • Unraveling Demographic Patterns in Hepatitis B Clinical and Laboratory Profiles: Insights From a Ghanaian Cohort: A Retrospective Study
    Napoleon Bellua Sam, Saeed Folorunsho Majeed, Adams Dramani
    Health Science Reports.2025;[Epub]     CrossRef
  • Head‐to‐Head Comparison of Long‐Term HCC Risk of Antivirals‐Treated Versus Untreated Low‐Level Viremia in HBV‐Compensated Cirrhosis
    Nobuharu Tamaki, Daniel Q. Huang, Hyung Woong Lee, Soo Young Park, Yu Rim Lee, Dong Hyun Sinn, Tae Seop Lim, Hiroyuki Marusawa, Seng Gee Lim, Hironori Ochi, Masahiko Kondo, Yasushi Uchida, Haruhiko Kobashi, Koichiro Furuta, Masayuki Kurosaki, Beom Kyung K
    Journal of Gastroenterology and Hepatology.2025; 40(6): 1595.     CrossRef
  • Assessing Liver Fibrosis in Chronic Hepatitis B: Liver Biopsy or Non-Invasive Fibrosis Markers?
    Deniz Borcak, Zuhal Yesilbag, Yusuf Emre Ozdemir, Adile Sevde Demir, Esra Salim Dogdas, Aysegul Inci Sezen, Esra Canbolat Unlu, Sevtap Senoglu, Hayat Kumbasar Karaosmanoglu, Kadriye Kart Yasar
    Journal of Clinical Medicine.2025; 14(22): 8164.     CrossRef
  • Recent Trends in Noninvasive Tests for Assessing Hepatic Fibrosis in Patients with Chronic Liver Disease
    Jung Hwan Yu
    The Korean Journal of Medicine.2024; 99(5): 232.     CrossRef
  • Noninvasive Imaging Test to Assess Liver Fibrosis: Vibration-controlled Transient Elastography
    Mi Na Kim
    The Korean Journal of Gastroenterology.2024; 84(5): 201.     CrossRef
  • Liver Fibrosis Assessment in Chronic Liver Diseases Using Elastography: A Comprehensive Review of Vibration-Controlled Transient Elastography and Shear Wave Elastography
    Han Ah Lee
    Clinical Ultrasound.2024; 9(2): 70.     CrossRef
  • 5,134 View
  • 127 Download
  • 5 Web of Science
  • Crossref

Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using vibration-controlled transient elastography: Systematic review and meta-analysis
Young-Joo Jin, Hee Yeon Kim, Young Ju Suh, Chae Hyeon Lee, Jung Hwan Yu, Mi Na Kim, Ji Won Han, Han Ah Lee, Jihyun An, Young Eun Chon, Dae Won Jun, Miyoung Choi, Seung Up Kim
Clin Mol Hepatol 2024;30(Suppl):S159-S171.
Published online July 23, 2024
DOI: https://doi.org/10.3350/cmh.2024.0163
Backgrounds/Aims
Liver stiffness measurement (LSM) using vibration-controlled transient elastography (VCTE) can assess fibrotic burden in chronic liver diseases. The systematic review and meta-analysis was conducted to determine whether LSM using VCTE can predict the risk of development of hepatocellular carcinoma (HCC) in chronic hepatitis B (CHB) patients.
Methods
A systematic literature search of the Ovid-Medline, EMBASE, Cochrane, and KoreaMed databases (from January 2010 to June 2023) was conducted. Of the 1,345 individual studies identified, 10 studies that used VCTE were finally registered. Hazard ratios (HRs) and the 95% confidence intervals (CIs) were considered summary estimates of treatment effect sizes of ≥11 kilopascal (kPa) standard for HCC development. Meta-analysis was performed using the restricted Maximum Likelihood random effects model.
Results
Among the ten studies, data for risk ratios for HCC development could be obtained from nine studies. When analyzed for the nine studies, the HR for HCC development was high at 3.33 (95% CI, 2.45–4.54) in CHB patients with a baseline LSM of ≥11 kPa compared to patients who did not. In ten studies included, LSM of ≥11 kPa showed the sensitivity and specificity for predicting HCC development were 61% (95% CI, 50–71%) and 78% (95% CI, 66–86%), respectively, and the diagnostic accuracy was 0.74 (95% CI, 0.70–0.77).
Conclusions
The risk of HCC development was elevated in CHB patients with VCTE-determined LSM of ≥11 kPa. This finding suggests that VCTE-determined LSM values may aid the risk prediction of HCC development in CHB patients.

Citations

Citations to this article as recorded by  Crossref logo
  • The use of transient elastography for predicting hepatocellular carcinoma in chronic hepatitis B patients: Editorial on “Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using vibration-controlled transient elastography: S
    Mirko Zoncapè, Emmanuel A. Tsochatzis
    Clinical and Molecular Hepatology.2025; 31(1): 268.     CrossRef
  • Unraveling Demographic Patterns in Hepatitis B Clinical and Laboratory Profiles: Insights From a Ghanaian Cohort: A Retrospective Study
    Napoleon Bellua Sam, Saeed Folorunsho Majeed, Adams Dramani
    Health Science Reports.2025;[Epub]     CrossRef
  • A Review of Risk Prediction Model for Hepatocellular Carcinoma in Chronic Hepatitis B
    Jiwon Yang, Mark D. Muthiah, Won-Mook Choi
    Current Hepatology Reports.2025;[Epub]     CrossRef
  • Head‐to‐Head Comparison of Long‐Term HCC Risk of Antivirals‐Treated Versus Untreated Low‐Level Viremia in HBV‐Compensated Cirrhosis
    Nobuharu Tamaki, Daniel Q. Huang, Hyung Woong Lee, Soo Young Park, Yu Rim Lee, Dong Hyun Sinn, Tae Seop Lim, Hiroyuki Marusawa, Seng Gee Lim, Hironori Ochi, Masahiko Kondo, Yasushi Uchida, Haruhiko Kobashi, Koichiro Furuta, Masayuki Kurosaki, Beom Kyung K
    Journal of Gastroenterology and Hepatology.2025; 40(6): 1595.     CrossRef
  • Discovering the metabolic pathway of liver disease by breath mass spectrometry combined with machine learning
    Xuanzhu Li, Wenbo Zhang, Tongtong Yang, Ying Zhang, Rui Su
    Journal of Pharmaceutical and Biomedical Analysis.2025; 265: 116988.     CrossRef
  • Future Perspectives of Liver Research in the Asia‐Pacific Region: Focus on Hepatitis B and C
    Beom Kyung Kim
    Journal of Gastroenterology and Hepatology.2025; 40(8): 1855.     CrossRef
  • Correspondence to editorial 1 on “Baveno VI-SSM stratifies the risk of portal hypertension-related events in patients with HBV-related cirrhosis”
    Haiyu Wang, Jinjun Chen
    Clinical and Molecular Hepatology.2025;[Epub]     CrossRef
  • EASL 2025 indications revisited: phase-specific outcomes with and without nucleos(t)ide analogue therapy in chronic hepatitis B virus infection
    Shichuan Tang, Tingfeng Huang, Ruijing Tang, Kongying Lin, Cong Luo, Yubing Shen, Kailing Zhang, Yidan Tang, Jie Kong, Zhenwei Chen, Jun Fu, Qizhu Lin, Luobin Guo, Yeye Wu, Yuntong Li, Jianxi Zhang, Zhenghong Sun, Penghui You, Daichang Zhang, Yanxin Chen,
    Gut.2025; : gutjnl-2025-335449.     CrossRef
  • The Evolving Application of Ultrasound in the Precision Management of Small Hepatocellular Carcinoma
    Xin Guan, Xinyuan Hu, Hong Han, Dezhi Zhang, Huixiong Xu
    Advanced Ultrasound in Diagnosis and Therapy.2025; 9(4): 375.     CrossRef
  • 5,500 View
  • 135 Download
  • 10 Web of Science
  • Crossref

Correspondence

Hepatic neoplasm

Correspondence to editorial on “Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study”
Young Eun Chon, Dong Yun Kim, Hong Jae Chon, Do Young Kim
Clin Mol Hepatol 2024;30(4):1005-1008.
Published online May 30, 2024
DOI: https://doi.org/10.3350/cmh.2024.0394

Citations

Citations to this article as recorded by  Crossref logo
  • Multiple drugs

    Reactions Weekly.2025; 2068(1): 279.     CrossRef
  • 3,960 View
  • 73 Download
  • Crossref

Original Articles

Hepatic neoplasm

Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study
Young Eun Chon, Dong Yun Kim, Mi Na Kim, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Sang Hoon Ahn, Yeonjung Ha, Joo Ho Lee, Kwan Sik Lee, Beodeul Kang, Jung Sun Kim, Hong Jae Chon, Do Young Kim
Clin Mol Hepatol 2024;30(3):345-359.
Published online March 12, 2024
DOI: https://doi.org/10.3350/cmh.2023.0553
Background/Aims
Atezolizumab plus bevacizumab (ATE+BEV) therapy has become the recommended first-line therapy for patients with unresectable hepatocellular carcinoma (HCC) because of favorable treatment responses. However, there is a lack of data on sequential regimens after ATE+BEV treatment failure. We aimed to investigate the clinical outcomes of patients with advanced HCC who received subsequent systemic therapy for disease progression after ATE+BEV.
Methods
This multicenter, retrospective study included patients who started second-line systemic treatment with sorafenib or lenvatinib after HCC progressed on ATE+BEV between August 2019 and December 2022. Treatment response was assessed using the Response Evaluation Criteria in Solid Tumors (version 1.1.). Clinical features of the two groups were balanced through propensity score (PS) matching.
Results
This study enrolled 126 patients, 40 (31.7%) in the lenvatinib group, and 86 (68.3%) in the sorafenib group. The median age was 63 years, and males were predominant (88.1%). In PS-matched cohorts (36 patients in each group), the
objective
response rate was similar between the lenvatinib- and sorafenib-treated groups (5.6% vs. 8.3%; P=0.643), but the disease control rate was superior in the lenvatinib group (66.7% vs. 22.2%; P<0.001). Despite the superior progression- free survival (PFS) in the lenvatinib group (3.5 vs. 1.8 months, P=0.001), the overall survival (OS, 10.3 vs. 7.5 months, P=0.353) did not differ between the two PS-matched treatment groups.
Conclusions
In second-line therapy for unresectable HCC after ATE+BEV failure, lenvatinib showed better PFS and comparable OS to sorafenib in a real-world setting. Future studies with larger sample sizes and longer follow-ups are needed to optimize second-line treatment.

Citations

Citations to this article as recorded by  Crossref logo
  • EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma
    Bruno Sangro, Josepmaria Argemi, Maxime Ronot, Valerie Paradis, Tim Meyer, Vincenzo Mazzaferro, Peter Jepsen, Rita Golfieri, Peter Galle, Laura Dawson, Maria Reig
    Journal of Hepatology.2025; 82(2): 315.     CrossRef
  • Lenvatinib versus sorafenib as second-line therapy following progression on atezolizumab–bevacizumab in patients with unresectable hepatocellular carcinoma: a multicenter retrospective study from Korea and Japan
    Jaekyung Cheon, Shigeo Shimose, Hyung-Don Kim, Takashi Niizeki, Min-Hee Ryu, Tomotake Shirono, Baek-Yeol Ryoo, Hideki Iwamoto, Changhoon Yoo
    Journal of Cancer Research and Clinical Oncology.2025;[Epub]     CrossRef
  • Treatment for hepatocellular carcinoma after immunotherapy
    Landon L. Chan, Tsz Tung Kwong, Johnny C.W. Yau, Stephen L. Chan
    Annals of Hepatology.2025; 30(2): 101781.     CrossRef
  • Evaluating Sorafenib (SORA-2) as Second-Line Treatment for Unresectable Hepatocellular Carcinoma: A European Retrospective Multicenter Study
    Christian Möhring, Moritz Berger, Farsaneh Sadeghlar, Xin Zhou, Taotao Zhou, Malte Benedikt Monin, Kateryna Shmanko, Sabrina Welland, Friedrich Sinner, Birgit Schwacha-Eipper, Ulrike Bauer, Christoph Roderburg, Angelo Pirozzi, Najib Ben Khaled, Peter Schr
    Cancers.2025; 17(6): 972.     CrossRef
  • Therapeutic Sequences of Systemic Therapy After Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma: Real‐World Analysis of the IMMUreal Cohort
    Najib Ben Khaled, Valentina Zarka, Bernard Hobeika, Julia Schneider, Monika Rau, Alexander Weich, Hans Benno Leicht, Liangtao Ye, Ignazio Piseddu, Michael T. Dill, Arne Kandulski, Matthias Pinter, Ursula Ehmer, Peter Schirmacher, Jens U. Marquardt, Julia
    Alimentary Pharmacology & Therapeutics.2025; 61(11): 1755.     CrossRef
  • Application of the associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) technique in conversion therapy for hepatocellular carcinoma
    Jingyun Ning, Cao Dai, Qin Liu, Haoming Lin, Rui Zhang
    British Journal of Surgery.2025;[Epub]     CrossRef
  • Recent advances in polydopamine-coated metal–organic frameworks for cancer therapy
    Jingchao He, Guangtian Wang, Yongfang Zhou, Bin Li, Pan Shang
    Frontiers in Bioengineering and Biotechnology.2025;[Epub]     CrossRef
  • Targeting STAT3 by erianin to overcome sorafenib resistance in hepatocellular carcinoma: Integrated network pharmacology with molecular docking, dynamics simulations, and in vitro validation
    Zixian Liu, Ruoning Qian, Yuanchao Feng, Ruogu Qi, Zhengguang Zhang, Fuqiong Zhou
    Biochemical and Biophysical Research Communications.2025; 778: 152348.     CrossRef
  • PEGylated liposomal metformin overcomes pharmacokinetic barriers to trigger potent mitochondrial disruption and cell cycle arrest in hepatocellular carcinoma
    Zeinab A. Elzanaty, Medhat W. Shafaa, Seifeldin Elabed, Mohamed M. Omran
    Scientific Reports.2025;[Epub]     CrossRef
  • Multicenter Phase 2 Trial of Second-Line Regorafenib in Patients with Unresectable Hepatocellular Carcinoma after Progression on Atezolizumab plus Bevacizumab
    Jaekyung Cheon, Baek-Yeol Ryoo, Hong Jae Chon, Hyung-Don Kim, Min-Hee Ryu, Kyu-Pyo Kim, Beodeul Kang, Richard S. Finn, Stephen Lam Chan, Changhoon Yoo
    Liver Cancer.2025; 14(4): 446.     CrossRef
  • Development and validation of a risk prediction model for patients with hepatocellular carcinoma receiving atezolizumab–bevacizumab
    Heechul Nam, Dong Yun Kim, Do Young Kim, Ji Hoon Kim, Chang Wook Kim, Jaejun Lee, Keungmo Yang, Ji Won Han, Pil Soo Sung, Seung Kew Yoon, Hee Sun Cho, Hyun Yang, Si Hyun Bae, Soon Kyu Lee, Jung Hyun Kwon, Soon Woo Nam, Ahlim Lee, Do Seon Song, U Im Chang,
    Hepatology.2025;[Epub]     CrossRef
  • Multicenter phase II trial of lenvatinib in patients with advanced hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab
    Hyung-Don Kim, Sun Jin Sym, Hong Jae Chon, Moonho Kim, Jung Hun Kang, Baek-Yeol Ryoo, Choong-kun Lee, Joohyun Hong, Hyewon Ryu, Woo Kyun Bae, Hyeyeong Kim, Hyunho Kim, Jin Won Kim, Tae-Yong Kim, Changhoon Yoo
    Journal of Hepatology.2025;[Epub]     CrossRef
  • Lenvatinib versus sorafenib as second-line treatment post atezolizumab plus bevacizumab for hepatocellular carcinoma: the LEVIATHAN Study.
    Pasquale Lombardi, Jung Sun Kim, Giulia F. Manfredi, Ciro Celsa, Claudia A.M. Fulgenzi, Antonio D’Alessio, Bernardo Stefanini, Niraj C. Doshi, Emily Warmington, Thomas U. Marron, Matthias Pinter, Bernhard Scheiner, Beodeul Kang, Ho Yeong Lim, Wei-Fan Hsu,
    JHEP Reports.2025; : 101595.     CrossRef
  • Comparative analysis of lenvatinib use after atezolizumab plus bevacizumab versus lenvatinib as first-line therapy in unresectable hepatocellular carcinoma
    Kazuki Maesaka, Hayato Hikita, Yuki Tahata, Chinatsu Nishioka, Machiko Kai, Kumiko Shirai, Kazuhiro Murai, Yuki Makino, Yoshinobu Saito, Takahiro Kodama, Kazuyoshi Ohkawa, Masanori Miyazaki, Yasutoshi Nozaki, Takayuki Yakushijin, Ryotaro Sakamori, Nobuyuk
    Journal of Gastroenterology.2025;[Epub]     CrossRef
  • The potential of lenvatinib in breast cancer therapy
    Yuefeng Shang, Tong Liu, Wenjing Wang
    Medical Oncology.2024;[Epub]     CrossRef
  • Sorafenib and SIAIS361034, a novel PROTAC degrader of BCL-xL, display synergistic antitumor effects on hepatocellular carcinoma with minimal hepatotoxicity
    Xiaoyi Zhang, Yachuan Tao, Zhongli Xu, Biao Jiang, Xiaobao Yang, Taomin Huang, Wenfu Tan
    Biochemical Pharmacology.2024; 230: 116542.     CrossRef
  • Second-line systemic therapy after atezolizumab plus bevacizumab: Is it time to boldly go beyond the known?
    Edoardo G. Giannini
    Digestive and Liver Disease.2024; 56(12): 2077.     CrossRef
  • Correspondence to editorial on “Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study”
    Young Eun Chon, Dong Yun Kim, Hong Jae Chon, Do Young Kim
    Clinical and Molecular Hepatology.2024; 30(4): 1005.     CrossRef
  • Improved survival with second-line hepatic arterial infusion chemotherapy after atezolizumab-bevacizumab failure in hepatocellular carcinoma
    Ji Yeon Lee, Jaejun Lee, Suho Kim, Jae-sung Yoo, Ji Hoon Kim, Keungmo Yang, Ji Won Han, Jeong Won Jang, Jong Yong Choi, Seung Kew Yoon, Ho Jong Chun, Jung Suk Oh, Pil Soo Sung
    Frontiers in Oncology.2024;[Epub]     CrossRef
  • 9,426 View
  • 506 Download
  • 21 Web of Science
  • Crossref

Viral hepatitis

Core indicators related to the elimination of hepatitis B and C virus infection in South Korea: A nationwide study
Chang Hun Lee, Gwang Hyeon Choi, Hwa Young Choi, Sojung Han, Eun Sun Jang, Young Eun Chon, Young Chang, Kyung-Ah Kim, Do Young Kim, Hyung Joon Yim, Hye-Lin Kim, Sook-Hyang Jeong, In Hee Kim
Clin Mol Hepatol 2023;29(3):779-793.
Published online May 15, 2023
DOI: https://doi.org/10.3350/cmh.2023.0110
Background/Aims
To eliminate hepatitis B virus (HBV) and hepatitis C virus (HCV) according to the World Health Organization (WHO) criteria in 2021, this study investigated the national core indicators representing the current status of viral hepatitis B and C in South Korea.
Methods
We analyzed the incidence, linkage-to-care, treatment, and mortality rates of HBV and HCV infection using the integrated nationwide big data of South Korea.
Results
According to data from 2018–2020, the incidence of acute HBV infection in South Korea was 0.71 cases per 100,000 population; tthe linkage-to-care rate was only 39.4%. Among those who need hepatitis B treatment, the treatment rate was 67.3%, which was less than 80% reported in the WHO program index. The annual liver-related mortality due to HBV was 18.85 cases per 100,000 population, exceeding the WHO target of four; the most frequent cause of death was liver cancer (54.1%). The annual incidence of newly diagnosed HCV infection was 11.9 cases per 100,000 population, which was higher than the WHO impact target of five. Among HCV-infected patients, the linkage-to-care rate was 65.5% while the treatment rate was 56.8%, which were below the targets of 90% and 80%, respectively. The liver-related annual mortality rate due to HCV infection was 2.02 cases per 100,000 population.
Conclusions
Many of the current indicators identified in the Korean population did not satisfy the WHO criteria for validation of viral hepatitis elimination. Hence, a comprehensive national strategy should be urgently developed with continuous monitoring of the targets in South Korea.

Citations

Citations to this article as recorded by  Crossref logo
  • AI-Safe-C score: Assessing liver-related event risks in patients without cirrhosis after successful direct-acting antiviral treatment
    Huapeng Lin, Terry Cheuk-Fung Yip, Hye Won Lee, Xiangjun Meng, Jimmy Che-To Lai, Sang Hoon Ahn, Wenjing Pang, Grace Lai-Hung Wong, Lingfeng Zeng, Vincent Wai-Sun Wong, Victor de Lédinghen, Seung Up Kim
    Journal of Hepatology.2025; 82(3): 456.     CrossRef
  • Burden, trends, and predictions of liver cancer in China, Japan, and South Korea: analysis based on the Global Burden of Disease Study 2021
    Si Yang, Yujiao Deng, Yi Zheng, Jing Zhang, Dongdong He, Zhijun Dai, Changcun Guo
    Hepatology International.2025; 19(2): 441.     CrossRef
  • Contemporary awareness of viral hepatitis between 2012 and 2022 among Korean adults
    Donghee Kim, Won Kim, Aijaz Ahmed
    Clinical and Molecular Hepatology.2025; 31(1): e5.     CrossRef
  • Etiologic, epidemic, medical and economic aspects of hepatocellular carcinoma
    N. A. Vlasova, V. I. Apanasevich, E. V. Eliseeva, S. S. Startsev
    Сибирский научный медицинский журнал.2025; 45(1): 6.     CrossRef
  • HCV self-testing: Bridging screening gaps and ensuring cost-effectiveness for both high-risk and universal populations: Correspondence to editorial on “Self-testing strategy to eliminate hepatitis C as per World Health Organization’s goal: Analysis of dis
    Gyeongseon Shin, Beom Kyung Kim, SeungJin Bae, Hankil Lee, Sang Hoon Ahn
    Clinical and Molecular Hepatology.2025; 31(2): e163.     CrossRef
  • Universal self-testing as a cost-effective weapon to eliminate hepatitis C virus in the Republic of Korea: Editorial on “Self-testing strategy to eliminate hepatitis C as per World Health Organization’s goal: Analysis of disease burden and cost-effectiven
    Eun Sun Jang
    Clinical and Molecular Hepatology.2025; 31(2): 596.     CrossRef
  • Temporal and geospatial patterns of hepatitis C virus prevalence: a longitudinal examination using national health insurance service data in the Republic of Korea (2005–2022)
    Hwa Young Choi, Moran Ki
    BMC Public Health.2025;[Epub]     CrossRef
  • Correspondence to letter to the editor on “Contemporary awareness of viral hepatitis between 2012 and 2022 among Korean adults”
    Chang Hun Lee, In Hee Kim, Sook-Hyang Jeong
    Clinical and Molecular Hepatology.2025; 31(2): e149.     CrossRef
  • Incidence of Osteopenia or Osteoporosis in Asian Patients With Chronic Hepatitis B
    Hye Won Lee, Sungshin Kwon, Yeo Rae Moon, Hyunjung Ahn, Juyeon Lee, Sang‐Hoon Ahn
    Journal of Gastroenterology and Hepatology.2025; 40(6): 1586.     CrossRef
  • A 2024 global report on national policy, programmes, and progress towards hepatitis B elimination: findings from 33 hepatitis elimination profiles
    Lindsey Hiebert-Suwondo, Jana Manning, Rania A Tohme, Maria Buti, Loreta A Kondili, C Wendy Spearman, Nishi Prabdial-Sing, Victoria Turnier, Jeffrey V Lazarus, Imam Waked, John W Ward, Angelica Miranda, Aya Sugiyama, Behzad Hajarizadeh, Carlos Varaldo, Ca
    The Lancet Gastroenterology & Hepatology.2025; 10(7): 671.     CrossRef
  • Service delivery models and care cascade outcomes for people living with chronic hepatitis B: a global systematic review and meta-analysis
    Alexander J Stockdale, Bethany Holt, Ajeet Singh Bhadoria, Abhishek Sadasivan, Daniel Ikeda, Todd Pollack, Janus P Ong, Thuy Pham, David B Duong, Vy Nguyen, Gibril Ndow, Roger Chou, Philippa Easterbrook
    The Lancet Gastroenterology & Hepatology.2025; 10(11): 1013.     CrossRef
  • Prevalence, Clinical Characteristics, and Treatment Status of Hepatitis C Virus Infection among People Who Use Drugs in South Korea: A Prospective Multicenter Study
    Gwang Hyeon Choi, Young-Hoon Chon, Do Hoon Kwon, Sung Nam Jo, Og-Jin Jang, Kyung-Ah Kim, Dahye Baik, Eun Sun Jang, Sook-Hyang Jeong
    Gut and Liver.2025; 19(5): 725.     CrossRef
  • Etiological, Epidemiological, and Medical-Economic Aspects of Hepatocellular Carcinoma (A Review)
    N. A. Vlasova, V. I. Apanasevich, E. V. Eliseeva, S. S. Startsev
    Cell and Tissue Biology.2025; 19(6): 525.     CrossRef
  • Monitoring and evaluation of community interventions for viral hepatitis among migrants and refugees: a Delphi-based study
    Domenico Pascucci, Aina Nicolàs, Abdelrahman Taha, Jeffrey V Lazarus, Matteo Di Pumpo, Vittoria Tricomi, Francesco Di Berardino, Carlo La Vecchia, José A Perez-Molina, Giuseppe Colucci, Camila A Picchio, Angelo Maria Pezzullo, Stefania Boccia
    Journal of Global Health.2025;[Epub]     CrossRef
  • Effect of direct-acting antivirals on disease burden of hepatitis C virus infection in South Korea in 2007–2021: a nationwide, multicentre, retrospective cohort study
    Won Sohn, Soo Young Park, Tae Hee Lee, Young Eun Chon, In Hee Kim, Byung-Seok Lee, Ki Tae Yoon, Jae Young Jang, Yu Rim Lee, Su Jong Yu, Won-Mook Choi, Sang Gyune Kim, Dae Won Jun, Joonho Jeong, Ji Hoon Kim, Eun Sun Jang, Hwi Young Kim, Sung Bum Cho, Byoun
    eClinicalMedicine.2024; 73: 102671.     CrossRef
  • Linvencovir: Paving the way for functional cure in hepatitis B
    Jiwon Yang, Jonggi Choi
    Clinical and Molecular Hepatology.2024; 30(2): 164.     CrossRef
  • Higher FIB-4 index at baseline predicts development of liver cancer in a community-based cohort with viral hepatitis
    Makiko Kimura, Tomoki Nishikawa, Tetsuro Shimakami, Takeshi Terashima, Rika Horii, Masako Fukuda, Mika Yoshita, Noboru Takata, Tomoyuki Hayashi, Masaya Funaki, Kouki Nio, Hajime Takatori, Kuniaki Arai, Tatsuya Yamashita, Masao Honda, Junko Tanaka, Shuichi
    Global Health & Medicine.2024; 6(6): 404.     CrossRef
  • Activation of Nrf2 and FXR via Natural Compounds in Liver Inflammatory Disease
    Marta Belka, Aleksandra Gostyńska-Stawna, Maciej Stawny, Violetta Krajka-Kuźniak
    International Journal of Molecular Sciences.2024; 25(20): 11213.     CrossRef
  • Correspondence to editorial on “Core indicators related to the elimination of hepatitis B and C virus infection in South Korea: A nationwide study”
    Chang Hun Lee, In Hee Kim, Sook-Hyang Jeong
    Clinical and Molecular Hepatology.2024; 30(4): 997.     CrossRef
  • Elimination of viral hepatitis: How far are we?: Editorial on “Core indicators related to the elimination of hepatitis B and C virus infection in South Korea: A nationwide study”
    Eun Ju Cho
    Clinical and Molecular Hepatology.2024; 30(4): 663.     CrossRef
  • 8,654 View
  • 222 Download
  • 18 Web of Science
  • Crossref

Hepatic neoplasm

Hepatocellular carcinoma incidence is decreasing in Korea but increasing in the very elderly
Young Eun Chon, Seong Yong Park, Han Pyo Hong, Donghee Son, Jonghyun Lee, Eileen Yoon, Soon Sun Kim, Sang Bong Ahn, Soung Won Jeong, Dae Won Jun
Clin Mol Hepatol 2023;29(1):120-134.
Published online August 12, 2022
DOI: https://doi.org/10.3350/cmh.2021.0395
Background/Aims
A comprehensive analysis of trends in the incidence of hepatocellular carcinoma (HCC) is important for planning public health initiatives. We aimed to analyze the trends in HCC incidence in South Korea over 10 years and to predict the incidence for the year 2028.
Methods
Data from patients with newly diagnosed HCC between 2008 and 2018 were obtained from Korean National Health Insurance Service database. Age-standardized incidence rates (ASRs) were calculated to compare HCC incidence. A poisson regression model was used to predict the future incidence of HCC.
Results
The average crude incidence rate (CR) was 22.4 per 100,000 person-years, and the average ASR was 17.6 per 100,000 person-years between 2008 and 2018. The CR (from 23.9 to 21.2 per 100,000 person-years) and ASR (from 21.9 to 14.3 per 100,000 person-years) of HCC incidence decreased during the past ten years in all age groups, except in the elderly. The ASR of patients aged ≥80 years increased significantly (from 70.0 to 160.2/100,000 person-years; average annual percent change, +9.00%; P<0.001). The estimated CR (17.9 per 100,000 person-years) and ASR (9.7 per 100,000 person-years) of HCC incidence in 2028 was declined, but the number of HCC patients aged ≥80 years in 2028 will be quadruple greater than the number of HCC patients in 2008 (from 521 to 2,055), comprising 21.3% of all HCC patients in 2028.
Conclusions
The ASRs of HCC in Korea have gradually declined over the past 10 years, but the number, CR, and ASR are increasing in patients aged ≥80 years.

Citations

Citations to this article as recorded by  Crossref logo
  • Liver Cancer Risk Across Metabolic Dysfunction-Associated Steatotic Liver Disease and/or Alcohol: A Nationwide Study
    Byungyoon Yun, Heejoo Park, Sang Hoon Ahn, Juyeon Oh, Beom Kyung Kim, Jin-Ha Yoon
    American Journal of Gastroenterology.2025; 120(2): 410.     CrossRef
  • Liver cancer in 2021: Global Burden of Disease study
    En Ying Tan, Pojsakorn Danpanichkul, Jie Ning Yong, Zhenning Yu, Darren Jun Hao Tan, Wen Hui Lim, Benjamin Koh, Ryan Yan Zhe Lim, Ethan Kai Jun Tham, Kartik Mitra, Asahiro Morishita, Yao-Chun Hsu, Ju Dong Yang, Hirokazu Takahashi, Ming-Hua Zheng, Atsushi
    Journal of Hepatology.2025; 82(5): 851.     CrossRef
  • Therapeutic Efficacy Studies on the Monoterpenoid Hinokitiol in the Treatment of Different Types of Cancer
    Md. Shimul Bhuia, Raihan Chowdhury, Meher Afroz, Md. Showkot Akbor, Md. Sakib Al Hasan, Jannatul Ferdous, Rubel Hasan, Marcus Vinícius Oliveira Barros de Alencar, Mohammad S. Mubarak, Muhammad Torequl Islam
    Chemistry & Biodiversity.2025;[Epub]     CrossRef
  • Clinical Course and Prognosis of Long‐Term Survivors of Hepatocellular Carcinoma
    Soon Sun Kim, Jonghyun Lee, Sang Bong Ahn, Young Eun Chon, Eileen Yoon, Soung Won Jeong, Dae Won Jun
    Alimentary Pharmacology & Therapeutics.2025; 61(8): 1333.     CrossRef
  • Targeting glypican 3 by immunotoxins: the promise of immunotherapy in hepatocellular carcinoma
    Elham Rismani, Nikoo Hossein-Khannazer, Moustapha Hassan, Elahe Shams, Mustapha Najimi, Massoud Vosough
    Expert Opinion on Therapeutic Targets.2025; 29(1-2): 59.     CrossRef
  • A Prospective, Multicenter, Randomized, Noninferiority Trial of Stopad® Versus Tachosil® for Hemostasis After Liver Resection
    Seung Yeon Lim, Gi Hong Choi, Jin Hong Lim, Ho-Seong Han, Yoo-Seok Yoon, Hae Won Lee, Boram Lee, Yeshong Park, MeeYoung Kang, Jinju Kim, Hyelim Joo, Jai Young Cho
    Cancers.2025; 17(5): 757.     CrossRef
  • Management of hepatocellular carcinoma in elderly and adolescent/young adult populations
    Han Ah Lee
    Journal of Liver Cancer.2025; 25(1): 52.     CrossRef
  • Efficacy and safety of combined targeted therapy and immunotherapy versus targeted monotherapy in older patients with uHCC
    Yu Li, Jian-Hong Zhong, Xiao-Dong Zhu, Chuang-Ye Han, Jia-Bei Wang, Hong-Zhi Liu, Kuan Hu, Yang-Xun Pan, Hui-Chuan Sun, Tao Peng, Lian-Xin Liu, Yong-Yi Zeng, Le-Du Zhou, Li Xu, Nan-Ya Wang
    Frontiers in Oncology.2025;[Epub]     CrossRef
  • Head‐to‐Head Comparison of Long‐Term HCC Risk of Antivirals‐Treated Versus Untreated Low‐Level Viremia in HBV‐Compensated Cirrhosis
    Nobuharu Tamaki, Daniel Q. Huang, Hyung Woong Lee, Soo Young Park, Yu Rim Lee, Dong Hyun Sinn, Tae Seop Lim, Hiroyuki Marusawa, Seng Gee Lim, Hironori Ochi, Masahiko Kondo, Yasushi Uchida, Haruhiko Kobashi, Koichiro Furuta, Masayuki Kurosaki, Beom Kyung K
    Journal of Gastroenterology and Hepatology.2025; 40(6): 1595.     CrossRef
  • Effectiveness of herbal medicine for liver cancer treatment as revealed by a bibliometric and visualization analysis
    Yusha Shi, Juwei Wang, Yahui Zhang, Kai Wu, Yibo Zhu, Kaiwen Yan, Qin Ouyang
    Frontiers in Oncology.2025;[Epub]     CrossRef
  • Hepatocellular Carcinoma in South Indian Population: Clinical Profile and AFP Correlation with Radiological Tumor Size
    Sahil Ahmad, Shubha Seshadri
    Journal of Pharmacy and Bioallied Sciences.2025; 17(Suppl 2): S1940.     CrossRef
  • Overall survival was inferior in octogenarians with early-stage hepatocellular carcinoma undergoing percutaneous radiofrequency ablation
    Yi-Hao Yen, Kwong-Ming Kee, Chao-Hung Hung, Chien-Hung Chen, Tsung-Hui Hu, Jing-Houng Wang, Sheng-Nan Lu, Chih-Yun Lin
    The American Journal of the Medical Sciences.2025; 370(3): 278.     CrossRef
  • Symptoms, Unmet Needs, and Length of Hospital Stay among Older Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization
    Jein Seon, Songran Kim, Juyeon Kim, Mira Kim, Hyekyung Kim
    Asian Oncology Nursing.2025; 25(2): 100.     CrossRef
  • Changes in antiviral treatment rate for hepatitis B virus before hepatocellular carcinoma diagnosis: a nationwide Korean study
    Young Eun Chon, Jonghyun Lee, Eileen L. Yoon, Soon Sun Kim, Sang Bong Ahn, Soung Won Jeong, Dae Won Jun
    European Journal of Gastroenterology & Hepatology.2025;[Epub]     CrossRef
  • Pre- and postoperative predictors of extrahepatic recurrence after curative resection for hepatocellular carcinoma
    Chang Hun Lee, Yun Chae Lee, Seung Young Seo, Ga Ram You, Hoon Gil Jo, Sung Bum Cho, Eun Young Cho, In Hee Kim, Sung Kyu Choi, Jae Hyun Yoon
    BMC Cancer.2025;[Epub]     CrossRef
  • 15-Year Trends in Hepatocellular Carcinoma: Epidemiology, Treatment, and Outcomes from a Hospital-Based Registry
    Songgyung Kim, Jina Park, Won-Mook Choi, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim, Han Chu Lee, Ki-Hun Kim, Jonggi Choi
    Gut and Liver.2025; 19(5): 746.     CrossRef
  • Global strategies and actions to eliminate hepatitis B virus infection
    Chih-Lin Lin, Jia-Horng Kao
    Clinical and Molecular Hepatology.2025; 31(4): 1197.     CrossRef
  • Bioactive compound D-Pinitol-loaded graphene oxide-chitosan-folic acid nanocomposite induced apoptosis in human hepatoma HepG-2 cells
    Ibrahim Abdel Aziz Ibrahim, Abdullah R. Alzahrani, Ibrahim M. Alanazi, Naiyer Shahzad, Imran Shahid, Alaa Hisham Falemban, Mohd Fahami Nur Azlina, Palanisamy Arulselvan
    Journal of Drug Delivery Science and Technology.2024; 92: 105282.     CrossRef
  • Itraconazole halts hepatocellular carcinoma progression by modulating sonic hedgehog signaling in rats: A novel therapeutic approach
    Osama A. Mohammed, Ahmed S. Doghish, Lobna A. Saleh, Mushabab Alghamdi, Mohannad Mohammad S. Alamri, Jaber Alfaifi, Masoud I.E. Adam, Muffarah Hamid Alharthi, Abdullah M. Alshahrani, Abdullah Hassan Alhalafi, Waad Fuad BinAfif, Assad Ali Rezigalla, Mustaf
    Pathology - Research and Practice.2024; 253: 155086.     CrossRef
  • Radiofrequency Ablation versus Surgical Resection in Elderly Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
    Jeong-Ju Yoo, Sujin Koo, Gi Hong Choi, Min Woo Lee, Seungeun Ryoo, Jungeun Park, Dong Ah Park
    Current Oncology.2024; 31(1): 324.     CrossRef
  • Harnessing the supremacy of MEG3 LncRNA to defeat gastrointestinal malignancies
    H.H. Rashwan, A.M. Taher, H.A. Hassan, A.A. Awaji, C.J. Kiriacos, R.A. Assal, R.A. Youness
    Pathology - Research and Practice.2024; 256: 155223.     CrossRef
  • Projected Incidence of Hepatobiliary Cancers and Trends Based on Age, Race, and Gender in the United States
    Michael H. Storandt, Sri Harsha Tella, Mikolaj A. Wieczorek, David Hodge, Julia K. Elrod, Philip S. Rosenberg, Zhaohui Jin, Amit Mahipal
    Cancers.2024; 16(4): 684.     CrossRef
  • A Prospective Analysis of the Effects of a Powder-Type Hemostatic Agent on the Short-Term Outcomes after Liver Resection
    MeeYoung Kang, Jai Young Cho, Ho-Seong Han, Yoo-Seok Yoon, Hae Won Lee, Boram Lee, Yeshong Park, Jinju Kim
    Medicina.2024; 60(2): 278.     CrossRef
  • Achieving Sufficient Therapeutic Outcomes of Surgery in Elderly Hepatocellular Carcinoma Patients through Appropriate Selection
    Han Ah Lee
    Gut and Liver.2024; 18(4): 556.     CrossRef
  • Current Insights into Molecular Mechanisms and Potential Biomarkers for Treating Radiation-Induced Liver Damage
    Biki Saha, Sneha Pallatt, Antara Banerjee, Abhijit G. Banerjee, Rupak Pathak, Surajit Pathak
    Cells.2024; 13(18): 1560.     CrossRef
  • Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using vibration-controlled transient elastography: Systematic review and meta-analysis
    Young-Joo Jin, Hee Yeon Kim, Young Ju Suh, Chae Hyeon Lee, Jung Hwan Yu, Mi Na Kim, Ji Won Han, Han Ah Lee, Jihyun An, Young Eun Chon, Dae Won Jun, Miyoung Choi, Seung Up Kim
    Clinical and Molecular Hepatology.2024; 30(Suppl): S159.     CrossRef
  • Incorporating ALBI Grade with Geriatric Nutritional Risk Index Enhances Hepatocellular Carcinoma Risk Stratification
    Heechul Nam, Pil Soo Sung, Sung Won Lee, Do Seon Song, Jung Hyun Kwon, Jeong Won Jang, Chang Wook Kim, Si Hyun Bae
    Liver Cancer.2024; : 1.     CrossRef
  • Peripheral immune signatures associated with the risk of hepatocarcinogenesis in cirrhotic Egyptian HCV patients before and after treatment with direct-acting antivirals
    Reem El-Shenawy, Rehab I. Moustafa, Naiera M. Helmy, Yasmine S. El-Abd, Ashraf A. Tabll, Yasser K. Elesnawy, Heba Shawky
    Virology Journal.2024;[Epub]     CrossRef
  • Chebulinic Acid Ameliorates Diethylnitrosamine-Induced Hepatocarcinogenesis in Rats by Inhibiting AKT/mTOR Activation and Inhibits Liver Cancer Cell (HepG2) Proliferation
    Zhidong Fu, Lihui Jiang
    Revista Brasileira de Farmacognosia.2024; 35(1): 101.     CrossRef
  • Albumin–Bilirubin Grade as a Valuable Predictor of Recurrence and Prognosis in Patients with Hepatocellular Carcinoma Following Radiofrequency Ablation
    Chang Hun Lee, Ga Ram You, Hoon Gil Jo, Chung Hwan Jun, Eun Young Cho, In Hee Kim, Sung Kyu Choi, Jae Hyun Yoon
    Cancers.2024; 16(24): 4167.     CrossRef
  • Metabolic Dysfunction-associated Steatotic Liver Disease–related Hepatocellular Carcinoma: Current Research Insights
    Ho Soo Chun, Minjong Lee, Tae Hun Kim
    Journal of Digestive Cancer Research.2024; 12(3): 184.     CrossRef
  • The emerging age-pattern changes of patients with hepatocellular carcinoma in Korea
    Yuri Cho, Bo Hyun Kim, Joong-Won Park
    Clinical and Molecular Hepatology.2023; 29(1): 99.     CrossRef
  • The latest global burden of liver cancer: A past and present threat
    Joo Hyun Oh, Dae Won Jun
    Clinical and Molecular Hepatology.2023; 29(2): 355.     CrossRef
  • Comparison of Open versus Laparoscopic Approaches in Salvage Hepatectomy for Recurrent Hepatocellular Carcinoma after Radiofrequency Ablation
    Yeshong Park, Jai Young Cho, Ho-Seong Han, Yoo-Seok Yoon, Hae Won Lee, Boram Lee, MeeYoung Kang, Jinju Kim
    Medicina.2023; 59(7): 1243.     CrossRef
  • Diagnostic Performance of the Fibrosis-4 Index and Nonalcoholic Fatty Liver Disease Fibrosis Score in Lean Adults With Nonalcoholic Fatty Liver Disease
    Huiyul Park, Eileen L. Yoon, Takanori Ito, Ae Jeong Jo, Mimi Kim, Jonghyun Lee, Hye-Lin Kim, Taeang Arai, Masanori Atsukawa, Miwa Kawanaka, Hidenori Toyoda, Masatoshi Ishigami, Ming-Lung Yu, Dae Won Jun, Mindie H. Nguyen
    JAMA Network Open.2023; 6(8): e2329568.     CrossRef
  • Radiotherapy trend in elderly hepatocellular carcinoma: retrospective analysis of patients diagnosed between 2005 and 2017
    Bong Kyung Bae, Jeong Il Yu, Hee Chul Park, Myung Ji Goh, Yong-Han Paik
    Radiation Oncology Journal.2023; 41(2): 98.     CrossRef
  • Serum resistin and the risk for hepatocellular carcinoma in diabetic patients
    Mona Mohamed Ibrahim Abdalla
    World Journal of Gastroenterology.2023; 29(27): 4271.     CrossRef
  • Risk factors associated with late hepatocellular carcinoma detection in patients undergoing regular surveillance
    Sangmi Jang, Young-Joo Jin, Jin-Woo Lee, Dam Kwon, Jung Hwan Yu
    Medicine.2023; 102(32): e34637.     CrossRef
  • A nationwide study on the current treatment status and natural prognosis of hepatocellular carcinoma in elderly
    Jeong-Ju Yoo, Jayoun Lee, Gi Hong Choi, Min Woo Lee, Dong Ah Park
    Scientific Reports.2023;[Epub]     CrossRef
  • The efficacy of treatment for hepatocellular carcinoma in elderly patients
    Han Ah Lee, Sangheun Lee, Hae Lim Lee, Jeong Eun Song, Dong Hyeon Lee, Sojung Han, Ju Hyun Shim, Bo Hyun Kim, Jong Young Choi, Hyunchul Rhim, Do Young Kim
    Journal of Liver Cancer.2023; 23(2): 362.     CrossRef
  • Salvage Hepatectomy for Recurrent Hepatocellular Carcinoma after Radiofrequency Ablation: A Retrospective Cohort Study with Propensity Score-Matched Analysis
    Yeshong Park, Ho-Seong Han, Yoo-Seok Yoon, Chang Jin Yoon, Hae Won Lee, Boram Lee, MeeYoung Kang, Jinju Kim, Jai Young Cho
    Cancers.2023; 15(19): 4745.     CrossRef
  • Blood-based biomarkers for immune-based therapy in advanced HCC: Promising but a long way to go
    Pil Soo Sung, Isaac Kise Lee, Pu Reun Roh, Min Woo Kang, Jaegyoon Ahn, Seung Kew Yoon
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • 10,085 View
  • 259 Download
  • 44 Web of Science
  • Crossref

Snapshot

Hepatic neoplasm

Hepatocellular carcinoma statistics in South Korea
Young Eun Chon, Soung Won Jeong, Dae Won Jun
Clin Mol Hepatol 2021;27(3):512-514.
Published online June 21, 2021
DOI: https://doi.org/10.3350/cmh.2021.0171

Citations

Citations to this article as recorded by  Crossref logo
  • Liver cancer in Saudi Arabia: A registry-based nationwide descriptive epidemiological and survival analysis
    Nawal H. Almohammadi
    Cancer Epidemiology.2025; 94: 102731.     CrossRef
  • A Randomized, Double-Blind, Placebo-Controlled Trial Protocol Using the Fuzhengxiaoliu Patch for the Management of Primary Liver Cancer Pain
    Siman Li, Binding Wang, Jiayao Deng, Haiyan Li, Yong Wu, Yu Fang, Bohua Yan, Yu Chen
    Journal of Pain Research.2025; Volume 18: 33.     CrossRef
  • Changes in antiviral treatment rate for hepatitis B virus before hepatocellular carcinoma diagnosis: a nationwide Korean study
    Young Eun Chon, Jonghyun Lee, Eileen L. Yoon, Soon Sun Kim, Sang Bong Ahn, Soung Won Jeong, Dae Won Jun
    European Journal of Gastroenterology & Hepatology.2025;[Epub]     CrossRef
  • Spectrum of therapeutic options in hepatocellular carcinoma
    Hyun Phil Shin, Moonhyung Lee, Jung Won Jeon
    Journal of Exercise Rehabilitation.2025; 21(4): 190.     CrossRef
  • Three-dimensional bio-printed microtissues: precision medicine approach in primary liver cancer
    Hani Keshavarz Alikhani, Homeyra Seydi, Kosar Nouri, Fatemeh Majidi, Olga Smirnova, Zahra Heydari, Daria Kuznetsova, Anastasia Shpichka, Elham Rismani, Peter Timashev, Massoud Vosough
    Regenerative Medicine.2025; : 1.     CrossRef
  • Bioactive compound D-Pinitol-loaded graphene oxide-chitosan-folic acid nanocomposite induced apoptosis in human hepatoma HepG-2 cells
    Ibrahim Abdel Aziz Ibrahim, Abdullah R. Alzahrani, Ibrahim M. Alanazi, Naiyer Shahzad, Imran Shahid, Alaa Hisham Falemban, Mohd Fahami Nur Azlina, Palanisamy Arulselvan
    Journal of Drug Delivery Science and Technology.2024; 92: 105282.     CrossRef
  • Genetic and Metabolic Characteristics of Lean Nonalcoholic Fatty Liver Disease in a Korean Health Examinee Cohort
    Huiyul Park, Eileen L. Yoon, Goh Eun Chung, Eun Kyung Choe, Jung Ho Bae, Seung Ho Choi, Mimi Kim, Woochang Hwang, Hye-Lin Kim, Sun Young Yang, Dae Won Jun
    Gut and Liver.2024; 18(2): 316.     CrossRef
  • Incidentally found parotid gland lesion in 18F-FDG PET/CT for staging evaluation of patients with hepatocellular carcinoma: remote possibility of metastatic tumor or second primary salivary gland malignancy
    Jin Hyung Jung, Yoon Se Lee, Young Ho Jung, Seung-Ho Choi, Soon Yuhl Nam, Hyo Jung Cho, Minsu Kwon
    BMC Surgery.2024;[Epub]     CrossRef
  • Recent Hepatocellular Carcinoma Managements in Korea: Focus on the Updated Guidelines in 2022
    Yuri Cho, Bo Hyun Kim, Young-Suk Lim
    Digestive Disease Interventions.2024; 08(03): 169.     CrossRef
  • Gender-specific alteration of steroid metabolism and its impact on viral replication in a mouse model of hepatitis B virus infection
    Eun-Sook Park, Juhee Won, Sung Hyun Ahn, Ah Ram Lee, Donghyo Lee, Ju-Yeon Moon, Man Ho Choi, Kyun-Hwan Kim
    Animal Cells and Systems.2024; 28(1): 466.     CrossRef
  • Evolving trends in treatment patterns for hepatocellular carcinoma in Korea from 2008 to 2022: a nationwide population-based study
    Ji Won Han, Won Sohn, Gwang Hyeon Choi, Jeong Won Jang, Gi Hyeon Seo, Bo Hyun Kim, Jong Young Choi
    Journal of Liver Cancer.2024; 24(2): 274.     CrossRef
  • Managing Postembolization Syndrome Through a Machine Learning–Based Clinical Decision Support System
    Minkyeong Kang, Myoung Soo Kim
    CIN: Computers, Informatics, Nursing.2024; 42(11): 817.     CrossRef
  • Cancer immunogenic cell death via pyroptosis with CXCR4-targeted nanotoxins in hepatocellular carcinoma
    Yingbin Huang, Yihu Li, Rui He, Shuyi Dong, Zheng Zhao, Xingyuan Jiao
    Frontiers in Bioengineering and Biotechnology.2024;[Epub]     CrossRef
  • Unveiling novel prognostic biomarkers and therapeutic targets for HBV-associated hepatocellular carcinoma through integrated bioinformatic analysis
    Xue Ren, Niaoniao Feng
    Medicine.2024; 103(43): e40134.     CrossRef
  • Stage dependent microbial dynamics in hepatocellular carcinoma and adjacent normal liver tissues
    Hee Eun Jo, Sophallika Khom, Sumi Lee, Su Hyeon Cho, Shin Young Park, Ga Ram You, Hyosin Kim, Nah Ihm Kim, Jae-Ho Jeong, Jae Hyun Yoon, Misun Yun
    Scientific Reports.2024;[Epub]     CrossRef
  • Coinfection of Hepatitis B and C Viruses and Risk of Hepatocellular Carcinoma: Systematic Review and Meta-analysis
    Abdullah A. Awadh, Abdulrahman A. Alharthi, Basil A. Alghamdi, Seraj T. Alghamdi, Mohammed K. Baqays, Ibrahim S. Binrabaa, Israa A. Malli
    Journal of Global Infectious Diseases.2024; 16(4): 127.     CrossRef
  • Chebulinic Acid Ameliorates Diethylnitrosamine-Induced Hepatocarcinogenesis in Rats by Inhibiting AKT/mTOR Activation and Inhibits Liver Cancer Cell (HepG2) Proliferation
    Zhidong Fu, Lihui Jiang
    Revista Brasileira de Farmacognosia.2024; 35(1): 101.     CrossRef
  • Evidence-based clinical recommendations for hypofractionated radiotherapy: exploring efficacy and safety - Part 4: Liver and locally recurrent rectal cancer
    Hwa Kyung Byun, Gyu Sang Yoo, Soo-Yoon Sung, Jin-Ho Song, Byoung Hyuck Kim, Yoo-Kang Kwak, Yeon Joo Kim, Yeon-Sil Kim, Kyung Su Kim
    Radiation Oncology Journal.2024; 42(4): 247.     CrossRef
  • The emerging age-pattern changes of patients with hepatocellular carcinoma in Korea
    Yuri Cho, Bo Hyun Kim, Joong-Won Park
    Clinical and Molecular Hepatology.2023; 29(1): 99.     CrossRef
  • Factors associated with the survival outcomes of patients with untreated hepatocellular carcinoma: An analysis of nationwide data
    Min Jung Kwon, Soy Chang, Ji Hoon Kim, Ji Won Han, Jeong Won Jang, Jong Young Choi, Seung Kew Yoon, Pil Soo Sung
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • The latest global burden of liver cancer: A past and present threat
    Joo Hyun Oh, Dae Won Jun
    Clinical and Molecular Hepatology.2023; 29(2): 355.     CrossRef
  • Clinical practice guideline and real-life practice in hepatocellular carcinoma: A Korean perspective
    Myung Ji Goh, Dong Hyun Sinn, Jong Man Kim, Min Woo Lee, Dong Ho Hyun, Jeong Il Yu, Jung Yong Hong, Moon Seok Choi
    Clinical and Molecular Hepatology.2023; 29(2): 197.     CrossRef
  • What should be done to reduce the discrepancy between guidelines and real-life practice for hepatocellular carcinoma in Korea?
    Min Kyung Park, Yoon Jun Kim
    Clinical and Molecular Hepatology.2023; 29(2): 332.     CrossRef
  • Overview of Asian clinical practice guidelines for the management of hepatocellular carcinoma: An Asian perspective comparison
    Yuri Cho, Bo Hyun Kim, Joong-Won Park
    Clinical and Molecular Hepatology.2023; 29(2): 252.     CrossRef
  • Radiotherapy trend in elderly hepatocellular carcinoma: retrospective analysis of patients diagnosed between 2005 and 2017
    Bong Kyung Bae, Jeong Il Yu, Hee Chul Park, Myung Ji Goh, Yong-Han Paik
    Radiation Oncology Journal.2023; 41(2): 98.     CrossRef
  • Hepatocellular Carcinoma—Southeast Asia Updates
    Satender Pal Singh, Vinod Arora, Tushar Madke, Shiv Kumar Sarin
    The Cancer Journal.2023; 29(5): 259.     CrossRef
  • Unraveling the Janus-Faced Role of Autophagy in Hepatocellular Carcinoma: Implications for Therapeutic Interventions
    Thi Ha Nguyen, Tuan Minh Nguyen, Dinh Thi Minh Ngoc, Taesik You, Mi Kyung Park, Chang Hoon Lee
    International Journal of Molecular Sciences.2023; 24(22): 16255.     CrossRef
  • Risk Predictors of Post-Embolization Syndrome after Transarterial Chemoembolization by Sex: A Retrospective Study
    Han Byeol Lim, Myoung Soo Kim
    Korean Journal of Adult Nursing.2023; 35(4): 418.     CrossRef
  • Efficacy of Transarterial Chemoembolization (TACE) for Early-Stage Hepatocellular Carcinoma
    Moonhyung Lee, Hyun Phil Shin
    Medicina.2023; 59(12): 2174.     CrossRef
  • Healthy Spouses can be Considered as Living Liver Donors
    Okjoo Lee, Jong Man Kim, Sang Jin Kim, Jinsoo Rhu, Gyu‐Seong Choi, Jae‐Won Joh
    World Journal of Surgery.2022; 46(6): 1474.     CrossRef
  • Better survival of patients with hepatitis B virus-related hepatocellular carcinoma in South Korea: Changes in 16-years cohorts
    Sang Il Choi, Yuri Cho, Moran Ki, Bo Hyun Kim, In Joon Lee, Tae Hyun Kim, Seong Hoon Kim, Young Hwan Koh, Hyun Beom Kim, Eun Kyung Hong, Chang-Min Kim, Joong-Won Park, Hamidreza Karimi-Sari
    PLOS ONE.2022; 17(3): e0265668.     CrossRef
  • Changing epidemiology of hepatocellular carcinoma in Asia
    Chen‐hao Zhang, Yifei Cheng, Shu Zhang, Jia Fan, Qiang Gao
    Liver International.2022; 42(9): 2029.     CrossRef
  • Atezolizumab/Bevacizumab vs. Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Real-World, Multi-Center Study
    Beom Kyung Kim, Jaekyung Cheon, Hyeyeong Kim, Beodeul Kang, Yeonjung Ha, Do Young Kim, Seong Gyu Hwang, Young Eun Chon, Hong Jae Chon
    Cancers.2022; 14(7): 1747.     CrossRef
  • Association between Proton Pump Inhibitor Use and Risk of Hepatocellular Carcinoma: A Korean Nationally Representative Cohort Study
    Soungmun Kim, Seogsong Jeong, Sun Jae Park, Jooyoung Chang, Seulggie Choi, Yoosun Cho, Joseph C. Ahn, Gyeongsil Lee, Joung Sik Son, Sang Min Park
    Journal of Clinical Medicine.2022; 11(10): 2865.     CrossRef
  • Crosstalk between tumor-associated macrophages and neighboring cells in hepatocellular carcinoma
    Pil Soo Sung
    Clinical and Molecular Hepatology.2022; 28(3): 333.     CrossRef
  • Liquid biopsy for early detection and therapeutic monitoring of hepatocellular carcinoma
    Eun-Ji Choi, Young-Joon Kim
    Journal of Liver Cancer.2022; 22(2): 103.     CrossRef
  • Blood-based biomarkers for immune-based therapy in advanced HCC: Promising but a long way to go
    Pil Soo Sung, Isaac Kise Lee, Pu Reun Roh, Min Woo Kang, Jaegyoon Ahn, Seung Kew Yoon
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Surveillance for hepatocellular carcinoma: It is time to move forward
    Bo Hyun Kim, Yuri Cho, Joong-Won Park
    Clinical and Molecular Hepatology.2022; 28(4): 810.     CrossRef
  • Realization of improved outcomes following liver resection in hepatocellular carcinoma patients aged 75 years and older
    Jong Man Kim, Jinsoo Rhu, Sang Yun Ha, Gyu-Seong Choi, Choon Hyuck David Kwon, Gaabsoo Kim, Jae-Won Joh
    Annals of Surgical Treatment and Research.2021; 101(5): 257.     CrossRef
  • Atezolizumab/Bevacizumab vs. Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Real-World, Multi-Center Study
    Beom Kyung Kim, Jaekyung Cheon, Hyeyeong Kim, Beodeul Kang, Yeonjung Ha, Do Young Kim, Sung Kyu Hwang, Young Eun Chon, Hong Jae Chon
    SSRN Electronic Journal .2021;[Epub]     CrossRef
  • 13,052 View
  • 198 Download
  • 38 Web of Science
  • Crossref

Original Articles

Viral hepatitis

Association between hepatic steatosis and the development of hepatocellular carcinoma in patients with chronic hepatitis B
Yun Bin Lee, Yeonjung Ha, Young Eun Chon, Mi Na Kim, Joo Ho Lee, Hana Park, Kwang-il Kim, Soo-Hwan Kim, Kyu Sung Rim, Seong Gyu Hwang
Clin Mol Hepatol 2019;25(1):52-64.
Published online October 23, 2018
DOI: https://doi.org/10.3350/cmh.2018.0040
Background/Aims
Nonalcoholic fatty liver disease (NAFLD) is becoming a worldwide epidemic, and is frequently found in patients with chronic hepatitis B (CHB). We investigated the impact of histologically proven hepatic steatosis on the risk for hepatocellular carcinoma (HCC) in CHB patients without excessive alcohol intake.
Methods
Consecutive CHB patients who underwent liver biopsy from January 2007 to December 2015 were included. The association between hepatic steatosis (≥ 5%) and subsequent HCC risk was analyzed. Inverse probability weighting (IPW) using the propensity score was applied to adjust for differences in patient characteristics, including metabolic factors.
Results
Fatty liver was histologically proven in 70 patients (21.8%) among a total of 321 patients. During the median (interquartile range) follow-up of 5.3 (2.9–8.3) years, 17 of 321 patients (5.3%) developed HCC: 8 of 70 patients (11.4%) with fatty liver and 9 of 251 patients (3.6%) without fatty liver. The five-year cumulative incidences of HCC among patients without and with fatty liver were 1.9% and 8.2%, respectively (P=0.004). Coexisting fatty liver was associated with a higher risk for HCC (adjusted hazards ratio [HR], 3.005; 95% confidence interval [CI], 1.122–8.051; P=0.03). After balancing with IPW, HCC incidences were not significantly different between the groups (P=0.19), and the association between fatty liver and HCC was not significant (adjusted HR, 1.709; 95% CI, 0.404–7.228; P=0.47).
Conclusions
Superimposed NAFLD was associated with a higher HCC risk in CHB patients. However, the association between steatosis per se and HCC risk was not evident after adjustment for metabolic factors.

Citations

Citations to this article as recorded by  Crossref logo
  • High serum growth differentiation factor 15 is a risk factor for the occurrence of hepatocellular carcinoma in chronic hepatitis B patients treated with nucleos(t)ide analogs
    Emi Sometani, Hayato Hikita, Kazuhiro Murai, Hidenori Toyoda, Satoshi Tanaka, Tsugiko Oze, Jihyun Sung, Akiyoshi Shimoda, Makoto Fukuoka, Satoshi Shigeno, Keisuke Fukutomi, Kumiko Shirai, Yuki Tahata, Yoshinobu Saito, Akira Nishio, Kunimaro Furuta, Takahi
    Hepatology Research.2025; 55(1): 22.     CrossRef
  • Risk Stratification of Metabolic Risk Factors and Statin Use Associated With Liver and Nonliver Outcomes in Chronic Hepatitis B
    Xinrong Zhang, Vy H Nguyen, Leslie Yeeman Kam, Scott D Barnett, Linda Henry, Ramsey Cheung, Mindie H Nguyen
    The Journal of Infectious Diseases.2025; 231(4): 1079.     CrossRef
  • Coexisting steatotic liver disease is not associated with long-term liver-related events in patients with chronic hepatitis B
    Navavee Uman, Apichat Kaewdech, Pimsiri Sripongpun, Naichaya Chamroonkul, Teerha Piratvisuth
    Gastroenterology Report.2025;[Epub]     CrossRef
  • Association of concomitant MASLD and hepatitis B virus with clinical prognosis in hepatocellular carcinoma after curative resection
    Chih-Jan Ko
    American Journal of Cancer Research.2025; 15(2): 737.     CrossRef
  • Study on Ultrasound-Assisted Diagnosis of CHB Complicated with NAFLD Hepatic Fibrosis Based on Deep Learning
    Xiuling Huang, Shan Huang, Changfeng Dong, Nuo Chen, Yuxuan Wang, Changmiao Wang, Yongquan Zhang, Cheng Feng
    Journal of Imaging Informatics in Medicine.2025;[Epub]     CrossRef
  • The outcomes and mechanisms of chronic hepatitis B complicated by metabolic dysfunction-associated steatotic liver disease
    Mao-Ping Li, Kai-Zhong Luo
    Hepatobiliary & Pancreatic Diseases International.2025; 24(5): 476.     CrossRef
  • Impact of Metabolic Dysfunction-Associated Fatty Liver Disease of Varying Severity on Antiviral Treatment Outcomes and Clinical Prognosis in Patients with Chronic Hepatitis B: A Systematic Review and Meta-analysis
    Qianqian Zhu, Chengde Su, Mingdan Li, Yali Xu, Qian Liu, Ying Zhang, Xinyi Zhang, Qiuxiang Li, Huajun Wang, Yawen Luo, Ping Yang
    Infectious Diseases and Therapy.2025; 14(8): 1599.     CrossRef
  • Chronic hepatitis B: Is it time for expanded antiviral treatment?
    Manish Manrai, Atul A Jha, Aditya V Pachisia, Saurabh Dawra
    World Journal of Virology.2025;[Epub]     CrossRef
  • Hepatocellular carcinoma risk stratification to identify patients suitable for intensive surveillance in viral hepatitis: the SELECT score
    Yeun-Yoon Kim, Won Chang, Jeong Min Lee, Se Woo Kim, Jae Seok Bae, Jeongin Yoo, Sun Kyung Jeon, HeeSoo Kim, Young Hoon Kim, Jin-Young Choi, Eun Ju Cho, Yun Bin Lee, Sook-Hyang Jeong, Do Young Kim, Yunhee Choi, Jeong Hee Yoon
    European Radiology.2025;[Epub]     CrossRef
  • Influence of metabolic dysfunction-associated fatty liver disease on the prognosis of patients with HBV-related acute-on-chronic liver failure
    Rui-Min Lai, Li-Xi Yao, Shan Lin, Jia-Hui Zhou, Bing-Ping Liu, Zhao-Yi Liang, Tianbin Chen, Jia-Ji Jiang, Qi Zheng, Yueyong Zhu
    Expert Review of Gastroenterology & Hepatology.2024; 18(1-3): 103.     CrossRef
  • Review on article of effects of tenofovir alafenamide and entecavir in chronic hepatitis B virus patients
    Yu-Tong Sun, Qian-Qian Chen
    World Journal of Hepatology.2024; 16(1): 109.     CrossRef
  • Effect of metabolic dysfunction‑associated fatty liver disease on the risk of hepatocellular carcinoma in patients with chronic hepatitis B: A systematic review and meta‑analysis
    Sixing Shen, Lingyan Pan
    Experimental and Therapeutic Medicine.2024;[Epub]     CrossRef
  • Effect of Concurrent Metabolic Dysfunction-Associated Steatotic Liver Disease on Serial Non-invasive Fibrosis Markers in Chronic Hepatitis B
    Danny Con, Steven Tu, Daniel Clayton-Chubb, John S. Lubel, Amanda J. Nicoll, Rohit Sawhney, Stephen Bloom
    Digestive Diseases and Sciences.2024; 69(4): 1496.     CrossRef
  • Influence of nonalcoholic fatty liver disease on response to antiviral treatment in patients with chronic hepatitis B: A meta-analysis
    Shi-Yi Liu, Dian Wang, Jing Liu, Lu-Ping Yang, Gong-Ying Chen
    World Journal of Hepatology.2024; 16(3): 465.     CrossRef
  • Navigating the Nomenclature of Liver Steatosis: Transitioning from NAFLD to MAFLD and MASLD - Understanding Affinities and Differences
    Apichat Kaewdech, Pimsiri Sripongpun
    Siriraj Medical Journal.2024; 76(4): 234.     CrossRef
  • Nonalcoholic fatty liver disease in Sub-Saharan Africa: A descriptive study of the range of histopathological findings in the South-West zone of Nigeria
    Olusegun Sylvester Ojo, Olusegun Adekanle, Dennis Ndububa, Olawunmi Kolawole, Omolade Adefolabi Betiku
    Nigerian Journal of Gastroenterology and Hepatology.2024; 16(1): 42.     CrossRef
  • Hepatic macrophage niche: a bridge between HBV-mediated metabolic changes with intrahepatic inflammation
    Jun Wang, Hongzhou Lu, Qian Li
    Frontiers in Immunology.2024;[Epub]     CrossRef
  • Prevalence of nonalcoholic fatty liver disease in patients with hepatitis B: A meta-analysis
    Li Zhang, Hong-Di Wu, Yuan-Fang Qian, Hong-Yan Xu
    World Journal of Clinical Cases.2024; 12(25): 5749.     CrossRef
  • Chronic hepatitis B and metabolic dysfunction-associated steatotic liver disease: Metabolic risk factors are key drivers of hepatocellular carcinoma
    Gupse Adali, Huseyin Aykut, Nermin Mutlu Bilgic, Yusuf Yilmaz
    Heliyon.2024; 10(18): e37990.     CrossRef
  • Revolutionizing the understanding of liver disease: Metabolism, function and future
    Arnulfo E Morales-Galicia, Mariana M Ramírez-Mejía, Guadalupe Ponciano-Rodriguez, Nahum Méndez-Sánchez
    World Journal of Hepatology.2024; 16(12): 1365.     CrossRef
  • Hepatic steatosis: Ultrasound assessment using attenuation imaging (ATI) with liver biopsy correlation
    Christopher J Welman, Jacqualine Saunders, Marilyn Zelesco, Steven Abbott, Glenn Boardman, Oyekoya T Ayonrinde
    Journal of Medical Imaging and Radiation Oncology.2023; 67(1): 45.     CrossRef
  • Concomitant Diseases and Co-contribution on Progression of Liver Stiffness in Patients with Hepatitis B Virus Infection
    Chang-Hai Liu, Wei Jiang, Dong-Bo Wu, Qing-Min Zeng, You-Juan Wang, Hong Tang
    Digestive Diseases and Sciences.2023; 68(4): 1605.     CrossRef
  • The interplay of long noncoding RNAs and hepatitis B virus
    Nima Sarfaraz, Srinivas Somarowthu, Michael J. Bouchard
    Journal of Medical Virology.2023;[Epub]     CrossRef
  • Steatosis, HBV‐related HCC, cirrhosis, and HBsAg seroclearance: A systematic review and meta‐analysis
    Xianhua Mao, Ka Shing Cheung, Chengzhi Peng, Lung‐Yi Mak, Ho Ming Cheng, James Fung, Noam Peleg, Howard H.‐W. Leung, Rajneesh Kumar, Jeong‐Hoon Lee, Amir Shlomai, Man‐Fung Yuen, Wai‐Kay Seto
    Hepatology.2023; 77(5): 1735.     CrossRef
  • Letter: metabolic dysfunction‐associated fatty liver disease increases risk of all‐cause mortality in patients with chronic hepatitis C
    Qianwen Zhao, Yunlei Deng
    Alimentary Pharmacology & Therapeutics.2023; 57(2): 272.     CrossRef
  • The association of fatty liver and risk of hepatocellular carcinoma in HBV or HCV infected individuals: a systematic review and meta-analysis
    Cheng-Long Han, Bao-Wen Tian, Chun-Cheng Yang, Ya-Fei Yang, Yun-Long Ma, Zi-Niu Ding, Lun-Jie Yan, Hui Liu, Zhao-Ru Dong, Zhi-Qiang Chen, Jian-Guo Hong, Dong-Xu Wang, Tao Li
    Expert Review of Gastroenterology & Hepatology.2023; 17(2): 189.     CrossRef
  • Hepatitis B virus infection combined with nonalcoholic fatty liver disease: Interaction and prognosis
    Lili Liu, Hong Li, Yang Zhang, Jing Zhang, Zhenhuan Cao
    Heliyon.2023; 9(1): e13113.     CrossRef
  • Liver fibrosis is closely related to metabolic factors in metabolic associated fatty liver disease with hepatitis B virus infection
    Haifeng Lv, Yanming Jiang, Geli Zhu, Shiyi Liu, Dian Wang, Jie Wang, Ke Zhao, Jing Liu
    Scientific Reports.2023;[Epub]     CrossRef
  • Positive hepatitis B core antibody is associated with advanced fibrosis and mortality in nonalcoholic fatty liver disease
    Pengyan Zhang, Zhenqiu Liu, Hong Fan, Tingting Shi, Xinyu Han, Chen Suo, Xingdong Chen, Tiejun Zhang
    European Journal of Gastroenterology & Hepatology.2023; 35(3): 294.     CrossRef
  • A novel non‐invasive model for the prediction of advanced liver fibrosis in chronic hepatitis B patients with NAFLD
    Jian Wang, Rui Huang, Jiacheng Liu, Ruimin Lai, Yilin Liu, Chuanwu Zhu, Yuanwang Qiu, Zebao He, Shengxia Yin, Yuxin Chen, Xiaomin Yan, Weimao Ding, Qi Zheng, Jie Li, Chao Wu
    Journal of Viral Hepatitis.2023; 30(4): 287.     CrossRef
  • Baseline hepatocyte ballooning is a risk factor for adverse events in patients with chronic hepatitis B complicated with nonalcoholic fatty liver disease
    You-Wen Tan, Jia-Min Wang, Xing-Bei Zhou
    World Journal of Hepatology.2023; 15(2): 237.     CrossRef
  • Impact of MAFLD on the complications after hepatectomy in patients with HBV-related hepatocellular carcinoma
    Ke-Gong Xiong, Tai-Shun Lin, Jin-Feng Kong, Qing-Biao Lin, Li-Fang Chen, Kun-Yu Ke
    Medicine.2023; 102(9): e33062.     CrossRef
  • Pyroptosis, Metabolism, and Oxidation in Tumorigenesis: Mechanisms and Therapeutic Implications
    Qi Cao, Jia-Bao Zhang, Di-Yang Sun, Jiang-Tao Fu, Wen-Bin Wu, Xiao-Fei Chen, Dong-Jie Li, Pei Wang
    Antioxidants & Redox Signaling.2023; 39(7-9): 512.     CrossRef
  • The hepatitis B virus promotes the progression of non-alcoholic fatty liver disease through incomplete autophagy
    Yang Wang, Jiaxi Li, Shanshan Wang, Yuheng Pang, Pengxiang Liu, Bangxiang Xie, Shuangshuang Dou, Tongwang Yang, Xiaoni Liu, Ying Shi, Dexi Chen
    Free Radical Biology and Medicine.2023; 204: 326.     CrossRef
  • Impact of prior HBV, HAV, and HEV infection on non‐alcoholic fatty liver disease
    Stephanos Vassilopoulos, Markos Kalligeros, Athanasios Vassilopoulos, Fadi Shehadeh, Gregorio Benitez, Matthew Kaczynski, Ingrid Lazaridou, Kittichai Promrat, Jack R. Wands, Eleftherios Mylonakis
    Journal of Viral Hepatitis.2023; 30(8): 685.     CrossRef
  • Metabolic dysfunction-associated fatty liver disease and the risk of hepatocellular carcinoma
    Byeong Geun Song, Sung Chul Choi, Myung Ji Goh, Wonseok Kang, Dong Hyun Sinn, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Seung Woon Paik
    JHEP Reports.2023; 5(9): 100810.     CrossRef
  • Impact of fatty liver on long-term outcomes in chronic hepatitis B: a systematic review and matched analysis of individual patient data meta-analysis
    Yu Jun Wong, Vy H. Nguyen, Hwai-I Yang, Jie Li, Michael Huan Le, Wan-Jung Wu, Nicole Xinrong Han, Khi Yung Fong, Elizebeth Chen, Connie Wong, Fajuan Rui, Xiaoming Xu, Qi Xue, Xin Yu Hu, Wei Qiang Leow, George Boon-Bee Goh, Ramsey Cheung, Grace Wong, Vince
    Clinical and Molecular Hepatology.2023; 29(3): 705.     CrossRef
  • The Global Prevalence of Nonalcoholic Fatty Liver Disease and its Association With Cancers: Systematic Review and Meta-Analysis
    Nor Asiah Muhamad, Nur Hasnah Maamor, Fatin Norhasny Leman, Zuraifah Asrah Mohamad, Sophia Karen Bakon, Mohd Hatta Abdul Mutalip, Izzah Athirah Rosli, Tahir Aris, Nai Ming Lai, Muhammad Radzi Abu Hassan
    Interactive Journal of Medical Research.2023; 12: e40653.     CrossRef
  • Tenofovir alafenamide significantly increased serum lipid levels compared with entecavir therapy in chronic hepatitis B virus patients
    Rui-Min Lai, Shan Lin, Miao-Miao Wang, Na Li, Jia-Hui Zhou, Xiao-Yu Lin, Tian-Bin Chen, Yue-Yong Zhu, Qi Zheng
    World Journal of Hepatology.2023; 15(8): 964.     CrossRef
  • Performance of Serum-Based Scores for Identification of Mild Hepatic Steatosis in HBV Mono-infected and HBV–HIV Co-infected Adults
    Richard K. Sterling, Wendy C. King, Mandana Khalili, David E. Kleiner, Amanda S. Hinerman, Mark Sulkowski, Raymond T. Chung, Mamta K. Jain, M auricio Lisker-Melman, David K. Wong, Marc G. Ghany
    Digestive Diseases and Sciences.2022; 67(2): 676.     CrossRef
  • Should We Treat Immune Tolerant Chronic Hepatitis B? Lessons from Asia
    Madhumita Premkumar, Yogesh K. Chawla
    Journal of Clinical and Experimental Hepatology.2022; 12(1): 144.     CrossRef
  • Comparison of biochemical response during antiviral treatment in patients with chronic hepatitis B infection
    Si Ho Kim, Eun Ju Cho, Boo‐ok Jang, Kyunghan Lee, Jae Kyun Choi, Gwang Hyeon Choi, Jeong‐Hoon Lee, Su Jong Yu, Yoon Jun Kim, Yun Bin Lee, Jeong‐Hwan Yoon, Jin‐Wook Kim, Sook‐Hyang Jeong, Eun Sun Jang
    Liver International.2022; 42(2): 320.     CrossRef
  • Increased risk of hepatocellular carcinoma and mortality in chronic viral hepatitis with concurrent fatty liver
    Mi Na Kim, Kyungdo Han, Juhwan Yoo, Seong Gyu Hwang, Sang Hoon Ahn
    Alimentary Pharmacology & Therapeutics.2022; 55(1): 97.     CrossRef
  • Outcomes of Liver Resection for Metabolic Dysfunction-Associated Fatty Liver Disease or Chronic Hepatitis B-Related HCC
    Lei Liu, Si Xie, Yu-Xian Teng, Zhu-Jian Deng, Kang Chen, Hao-Tian Liu, Rong-Rui Huo, Xiu-Mei Liang, Ping-Ping Guo, Da-Long Yang, Liang Ma, Bang-De Xiang, Le-Qun Li, Jian-Hong Zhong
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Severe Hepatic Steatosis Is Associated With Low-Level Viremia and Advanced Fibrosis in Patients With Chronic Hepatitis B in North America
    Hin Hin Ko, Nishi H. Patel, Sarah Haylock-Jacobs, Karen Doucette, Mang M. Ma, Curtis Cooper, Erin Kelly, Magdy Elkhashab, Edward Tam, Robert Bailey, Alexander Wong, Gerald Minuk, Philip Wong, Scott K. Fung, Giada Sebastiani, Alnoor Ramji, Carla S. Coffin
    Gastro Hep Advances.2022; 1(1): 106.     CrossRef
  • MAFLD is Associated with the Risk of Liver Fibrosis and Inflammatory Activity in HBeAg-Negative CHB Patients
    Xiaoman Chen, Jing Zhou, Lili Wu, Xiang Zhu, Hong Deng
    Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2022; Volume 15: 673.     CrossRef
  • Validation for models for tumor recurrence after liver transplantation in hepatectomy patients
    Sung Joon Kim, Jong Man Kim, Nam-Joon Yi, Gyu-Seong Choi, Kwang-Woong Lee, Kyung-Suk Suh, Jae-Won Joh
    Annals of Surgical Treatment and Research.2022; 102(3): 131.     CrossRef
  • A Novel Noninvasive Diagnostic Model of HBV-Related Inflammation in Chronic Hepatitis B Virus Infection Patients With Concurrent Nonalcoholic Fatty Liver Disease
    Xuemei Tao, Lin Chen, Youfei Zhao, Yonggang Liu, Ruifang Shi, Bei Jiang, Yuqiang Mi, Liang Xu
    Frontiers in Medicine.2022;[Epub]     CrossRef
  • Hepatitis B Core-Related Antigen Is Useful for Predicting Phase and Prognosis of Hepatitis B e Antigen-Positive Patients
    Han Ah Lee, Hyun Woong Lee, Younhee Park, Hyon-Suk Kim, Yeon Seok Seo
    Journal of Clinical Medicine.2022; 11(6): 1729.     CrossRef
  • MAFLD enhances clinical practice for liver disease in the Asia-Pacific region
    Takumi Kawaguchi, Tsubasa Tsutsumi, Dan Nakano, Mohammed Eslam, Jacob George, Takuji Torimura
    Clinical and Molecular Hepatology.2022; 28(2): 150.     CrossRef
  • Precision medicine in the era of potent antiviral therapy for chronic hepatitis B
    Eileen L. Yoon, Dae Won Jun
    Journal of Gastroenterology and Hepatology.2022; 37(7): 1191.     CrossRef
  • Metabolic Risk Factors Are Associated with the Disease Severity and Prognosis of Hepatitis B Virus-Related Acute on Chronic Liver Failure
    Lu Chen, Jinjin Dai, Qing Xie, Xiaolin Wang, Wei Cai
    Gut and Liver.2022; 16(3): 456.     CrossRef
  • Impact of NAFLD on the outcome of patients with chronic hepatitis B in Asia
    Ming Yang, Lai Wei
    Liver International.2022; 42(9): 1981.     CrossRef
  • Therapeutic mechanisms and beneficial effects of non-antidiabetic drugs in chronic liver diseases
    Han Ah Lee, Young Chang, Pil Soo Sung, Eileen L. Yoon, Hye Won Lee, Jeong-Ju Yoo, Young-Sun Lee, Jihyun An, Do Seon Song, Young Youn Cho, Seung Up Kim, Yoon Jun Kim
    Clinical and Molecular Hepatology.2022; 28(3): 425.     CrossRef
  • Magnetic resonance imaging improves stratification of fibrosis and steatosis in patients with chronic liver disease
    Han Ah Lee, Seung-seob Kim, Jin-Young Choi, Yeon Seok Seo, Beom Jin Park, Ki Choon Sim, Seung Up Kim
    Abdominal Radiology.2022; 47(11): 3733.     CrossRef
  • Clinical impact and mechanisms of hepatitis B virus infection concurrent with non-alcoholic fatty liver disease
    Xin Tong, Yu Song, Shengxia Yin, Jian Wang, Rui Huang, Chao Wu, Junping Shi, Jie Li
    Chinese Medical Journal.2022; 135(14): 1653.     CrossRef
  • Nonalcoholic fatty liver disease versus metabolic-associated fatty liver disease: Prevalence, outcomes and implications of a change in name
    Cheng Han Ng, Daniel Q. Huang, Mindie H. Nguyen
    Clinical and Molecular Hepatology.2022; 28(4): 790.     CrossRef
  • Progress in understanding of association between metabolic associated fatty liver disease and viral infectious diseases
    Zhao-Chun Chi
    World Chinese Journal of Digestology.2022; 30(18): 783.     CrossRef
  • Interaction and Possible Mechanism between Non-Alcoholic Fatty Liver Disease and Chronic Hepatitis B
    博诗 陈
    Advances in Clinical Medicine.2022; 12(11): 10453.     CrossRef
  • Radiomics Analysis of Magnetic Resonance Proton Density Fat Fraction for the Diagnosis of Hepatic Steatosis in Patients With Suspected Non-Alcoholic Fatty Liver Disease
    Ki Choon Sim, Min Ju Kim, Yongwon Cho, Hyun Jin Kim, Beom Jin Park, Deuk Jae Sung, Na Yeon Han, Yeo Eun Han, Tae Hyung Kim, Yoo Jin Lee
    Journal of Korean Medical Science.2022;[Epub]     CrossRef
  • Clinical study of ganshuang granule combined with tenofovir in the treatment of chronic hepatitis B complicated with nonalcoholic fatty liver disease
    Changtian Su, Qin Yang
    Frontiers in Pharmacology.2022;[Epub]     CrossRef
  • NAFLD and HBV interplay - related mechanisms underlying liver disease progression
    Evanthia Tourkochristou, Stelios F. Assimakopoulos, Konstantinos Thomopoulos, Markos Marangos, Christos Triantos
    Frontiers in Immunology.2022;[Epub]     CrossRef
  • Metabolic syndromes, hepatitis B virus (HBV), and hepatitis C virus as three factors involved in the development of hepatic steatosis: a systematic review and meta-analysis
    Masoud Keikha, Amirhossein Sahebkar, Tannaz Jamialahmadi, Mohsen Karbalaei
    Reviews and Research in Medical Microbiology.2022; 33(3): 139.     CrossRef
  • Secondary prevention of hepatitis B virus‐related hepatocellular carcinoma with current antiviral therapies
    Jonggi Choi, Young‐Suk Lim
    The Kaohsiung Journal of Medical Sciences.2021; 37(4): 262.     CrossRef
  • HRD1 attenuates the high uptake of [18F]FDG in hepatocellular carcinoma PET imaging
    Ai-Mei Li, Xia-Wen Lin, Jing-Tao Shen, Min Li, Qi-Huang Zheng, Zheng-Yang Zhou, Ming Shi
    Nuclear Medicine and Biology.2021; 96-97: 27.     CrossRef
  • The FIB-4 Index Is a Useful Predictor for the Development of Hepatocellular Carcinoma in Patients with Coexisting Nonalcoholic Fatty Liver Disease and Chronic Hepatitis B
    Minah Kim, Yeonju Lee, Jun Sik Yoon, Minjong Lee, So Shin Kye, Sun Woong Kim, Yuri Cho
    Cancers.2021; 13(10): 2301.     CrossRef
  • Association of Metabolic Risk Factors With Risks of Cancer and All‐Cause Mortality in Patients With Chronic Hepatitis B
    Yun Bin Lee, Hyemi Moon, Jeong‐Hoon Lee, Eun Ju Cho, Su Jong Yu, Yoon Jun Kim, Fabien Zoulim, Juneyoung Lee, Jung‐Hwan Yoon
    Hepatology.2021; 73(6): 2266.     CrossRef
  • Pyroptosis: mechanisms and diseases
    Pian Yu, Xu Zhang, Nian Liu, Ling Tang, Cong Peng, Xiang Chen
    Signal Transduction and Targeted Therapy.2021;[Epub]     CrossRef
  • Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B
    Laurens A. van Kleef, Hannah S.J. Choi, Willem P. Brouwer, Bettina E. Hansen, Keyur Patel, Robert A. de Man, Harry L.A. Janssen, Robert J. de Knegt, Milan J. Sonneveld
    JHEP Reports.2021; 3(5): 100350.     CrossRef
  • Systematic review with meta‐analysis: prevalence of hepatic steatosis, fibrosis and associated factors in chronic hepatitis B
    Qi Zheng, Biyao Zou, Yuankai Wu, Yeehui Yeo, Huizhen Wu, Christopher D Stave, Ramsey C. Cheung, Mindie H. Nguyen
    Alimentary Pharmacology & Therapeutics.2021; 54(9): 1100.     CrossRef
  • Association of central obesity with hepatocellular carcinoma in patients with chronic hepatitis B receiving antiviral therapy
    Rong Fan, Junqi Niu, Hong Ma, Qing Xie, Jun Cheng, Huiying Rao, Xiaoguang Dou, Jianping Xie, Wei Zhao, Jie Peng, Zhiliang Gao, Hongbo Gao, Xinyue Chen, Jinjun Chen, Qiang Li, Hong Tang, Zhengang Zhang, Hong Ren, Mingliang Cheng, Xieer Liang, Chaonan Zhu,
    Alimentary Pharmacology & Therapeutics.2021; 54(3): 329.     CrossRef
  • Controlled attenuation parameter value and the risk of hepatocellular carcinoma in chronic hepatitis B patients under antiviral therapy
    Joo Hyun Oh, Hye Won Lee, Dong Hyun Sinn, Jun Yong Park, Beom Kyung Kim, Seung Up Kim, Do Young Kim, Sang Hoon Ahn, Wonseok Kang, Geum-Youn Gwak, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik, Yong-Han Paik
    Hepatology International.2021; 15(4): 892.     CrossRef
  • Chronic hepatitis B infection with concomitant hepatic steatosis: Current evidence and opinion
    Yi-Wen Shi, Rui-Xu Yang, Jian-Gao Fan
    World Journal of Gastroenterology.2021; 27(26): 3971.     CrossRef
  • The Prognostic Role of On-Treatment Liver Stiffness for Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B
    Hye Won Lee, Hyun Woong Lee, Jae Seung Lee, Yun Ho Roh, Hyein Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
    Journal of Hepatocellular Carcinoma.2021; Volume 8: 467.     CrossRef
  • REPLY:
    Yun Bin Lee, Juneyoung Lee
    Hepatology.2021; 74(2): 1135.     CrossRef
  • Reply
    Hye Won Lee, Beom Kyung Kim
    Clinical Gastroenterology and Hepatology.2020; 18(1): 264.     CrossRef
  • Magnetic resonance imaging of obesity and metabolic disorders: Summary from the 2019 ISMRM Workshop
    Houchun H. Hu, Rosa Tamara Branca, Diego Hernando, Dimitrios C. Karampinos, Jürgen Machann, Charles A. McKenzie, Holden H. Wu, Takeshi Yokoo, S. Sendhil Velan
    Magnetic Resonance in Medicine.2020; 83(5): 1565.     CrossRef
  • Abnormal CD44 activation of hepatocytes with nonalcoholic fatty accumulation in rat hepatocarcinogenesis
    Miao Fang, Min Yao, Jie Yang, Wen-Jie Zheng, Li Wang, Deng-Fu Yao
    World Journal of Gastrointestinal Oncology.2020; 12(1): 66.     CrossRef
  • Chronic hepatitis B and non‐alcoholic fatty liver disease: Conspirators or competitors?
    Jianbin Zhang, Shuangzhe Lin, Daixi Jiang, Mengting Li, Yuanwen Chen, Jun Li, Jiangao Fan
    Liver International.2020; 40(3): 496.     CrossRef
  • Earlier Alanine Aminotransferase Normalization During Antiviral Treatment Is Independently Associated With Lower Risk of Hepatocellular Carcinoma in Chronic Hepatitis B
    Jonggi Choi, Gi-Ae Kim, Seungbong Han, Young-Suk Lim
    American Journal of Gastroenterology.2020; 115(3): 406.     CrossRef
  • Approach to the patient with chronic hepatitis B and decompensated cirrhosis
    Mitchell L. Shiffman
    Liver International.2020; 40(S1): 22.     CrossRef
  • Presence of Hepatic Steatosis Does Not Increase the Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Over Long Follow-Up
    Chong Teik Lim, George Boon Bee Goh, Huihua Li, Tony Kiat-Hon Lim, Wei Qiang Leow, Wei Keat Wan, Rafay Azhar, Wan Cheng Chow, Rajneesh Kumar
    Microbiology Insights.2020;[Epub]     CrossRef
  • Risk of Hepatocellular Carcinoma With Tenofovir vs Entecavir in Patients With Chronic Hepatitis B
    Han Ah Lee, Yeon Seok Seo, Seung Up Kim
    Gastroenterology.2020; 158(8): 2310.     CrossRef
  • Radiologic Nonalcoholic Fatty Liver Disease Increases the Risk of Hepatocellular Carcinoma in Patients With Suppressed Chronic Hepatitis B
    Hyeki Cho, Young Chang, Jeong-Hoon Lee, Young Youn Cho, Joon Yeul Nam, Yun Bin Lee, Dong Ho Lee, Eun Ju Cho, Su Jong Yu, Yoon Jun Kim, Jeong Min Lee, Jung-Hwan Yoon
    Journal of Clinical Gastroenterology.2020; 54(7): 633.     CrossRef
  • A New Endemic of Concomitant Nonalcoholic Fatty Liver Disease and Chronic Hepatitis B
    Hira Hanif, Muzammil M. Khan, Mukarram J. Ali, Pir A. Shah, Jinendra Satiya, Daryl T.Y. Lau, Aysha Aslam
    Microorganisms.2020; 8(10): 1526.     CrossRef
  • Letter: fatty liver disease could have been a confounding factor for phase change in patients with chronic hepatitis B in the immune‐tolerant phase—authors' reply
    Han Ah Lee, Seung Up Kim
    Alimentary Pharmacology & Therapeutics.2020; 52(6): 1094.     CrossRef
  • The Effects of Hepatic Steatosis on the Natural History of HBV Infection
    Idrees Suliman, Noha Abdelgelil, Farah Kassamali, Tarek I. Hassanein
    Clinics in Liver Disease.2019; 23(3): 433.     CrossRef
  • 12,361 View
  • 375 Download
  • 91 Web of Science
  • Crossref

Viral hepatitis

Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide-naïve chronic hepatitis B patients in Korea: data from the clinical practice setting in a single-center cohort
Sung Soo Ahn, Young Eun Chon, Beom Kyung Kim, Seung Up Kim, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Jun Yong Park
Clin Mol Hepatol 2014;20(3):261-266.
Published online September 25, 2014
DOI: https://doi.org/10.3350/cmh.2014.20.3.261
Background/Aims

This study assessed the antiviral efficacy and safety of tenofovir disoproxil fumarate (TDF) for up to 12 months in Korean treatment-naïve chronic hepatitis B (CHB) patients.

Methods

A total of 411 treatment-naïve CHB patients who had been treated with TDF for at least 3 months (median 5.6) were consecutively enrolled. Clinical, biochemical, virological parameters and treatment adherence were routinely assessed every 3 months.

Results

The median age was 51.3 years, 63.0% of the patients were male, 49.6% were HBeAg (+), and 210 patients had liver cirrhosis. The median baseline HBV DNA was 5.98 (SD 1.68) log10 IU/mL. Among the patients completing week 48, 83.3% had a complete virologic response (CVR, <12 IU/mL by HBV PCR assay), and 88.2% had normalized levels of alanine aminotransferase (ALT). The cumulative probabilities of CVR at 3, 6, 9 and 12 months were 22.8%, 53.1%, 69.3% and 85.0%. During the follow-up period, 9.8% patients achieved HBeAg loss and 7.8% patients achieved HBeAg seroconversion. There was no virological breakthrough after initiating TDF. The most common TDF-related adverse event was gastrointestinal upset, and three patients discontinued TDF therapy. However, no serious life-threatening side effect was noted.

Conclusions

In a clinical practice setting, TDF was safe and highly effective when administered for 12 months to Korean treatment-naïve CHB patients.

Citations

Citations to this article as recorded by  Crossref logo
  • Comparative efficacy and safety of pegylated interferon-alpha monotherapy vs combination therapies with entecavir or tenofovir in chronic hepatitis B patients
    Huiqing Liang, Xiaoting Zheng, Qianguo Mao, Jiaen Yang, Qingfa Ruan, Chuncheng Wu, Yaoyu Liu, Siyan Chen, Luyun Zhang, Manying Zhang, Hongli Zhuang, Li Lin, Shaodong Chen, Hyun Jin Kwun
    Microbiology Spectrum.2025;[Epub]     CrossRef
  • Comparative risk of osteoporosis and fractures in chronic hepatitis B patients: Tenofovir disoproxil fumarate vs. entecavir in a Korean nationwide cohort
    Yoon E. Shin, Jae Young Kim, Hyuk Kim, Jeong Ju Yoo, Sang Gyune Kim, Young Seok Kim
    JHEP Reports.2025; 7(9): 101489.     CrossRef
  • Entecavir resistance mutations rtL180M/T184L/M204V combined with rtA200V lead to tenofovir resistance
    Dong Jiang, Jianghua Wang, Xuesen Zhao, Yuxin Li, Qun Zhang, Chuan Song, Hui Zeng, Xianbo Wang
    Liver International.2020; 40(1): 83.     CrossRef
  • Adverse events of nucleos(t)ide analogues for chronic hepatitis B: a systematic review
    Raquel Scherer de Fraga, Victor Van Vaisberg, Luiz Cláudio Alfaia Mendes, Flair José Carrilho, Suzane Kioko Ono
    Journal of Gastroenterology.2020; 55(5): 496.     CrossRef
  • A severe case of tenofovir-associated acute kidney injury requiring hemodialysis in a patient with chronic hepatitis B
    A Young Cho, Ju Hwan Oh, Hee-Chan Moon, Gum Mo Jung, Young Suk Lee, Yeong Jin Choi, In O Sun, Kwang Young Lee
    Kidney Research and Clinical Practice.2020; 39(3): 373.     CrossRef
  • Antiviral Efficacy of Tenofovir Monotherapy in Children with Nucleos(t)ide-naive Chronic Hepatitis B
    Jae Young Choe, Jae Sung Ko, Byung-Ho Choe, Jung Eun Kim, Ben Kang, Kyung Jae Lee, Hye Ran Yang
    Journal of Korean Medical Science.2018;[Epub]     CrossRef
  • Effect of tenofovir on renal function in patients with chronic hepatitis B
    Woo Jin Jung, Jae Young Jang, Won Young Park, Soung Won Jeong, Hee Jeong Lee, Sang Joon Park, Sae Hwan Lee, Sang Gyune Kim, Sang-Woo Cha, Young Seok Kim, Young Deok Cho, Hong Soo Kim, Boo Sung Kim, Suyeon Park, Baigal Baymbajav
    Medicine.2018; 97(7): e9756.     CrossRef
  • Treatment Efficacy and Safety of Tenofovir-Based Therapy in Chronic Hepatitis B: A Real Life Cohort Study in Korea
    Hyo Jun Ahn, Myeong Jun Song, Jeong Won Jang, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon, Haitao Guo
    PLOS ONE.2017; 12(1): e0170362.     CrossRef
  • Effects of Entecavir and Tenofovir on Renal Function in Patients with Hepatitis B Virus-Related Compensated and Decompensated Cirrhosis
    Jihye Park, Kyu Sik Jung, Hye Won Lee, Beom Kyung Kim, Seung Up Kim, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Jun Yong Park
    Gut and Liver.2017; 11(6): 828.     CrossRef
  • Treatment of Chronic Hepatitis B with Tenofovir Disoproxil Fumarate in Ivory Coast
    Ya Henriette Kissi Anzouan-Kacou, Adjeka Stanislas Doffou, Djeinabou Diallo, Demba Aboubacar Bangoura, Yacouba Adéhouni, Hatrydt Dimitri Kouamé, Alassan Kouamé Mahassadi, Fulgence Yao Bathaix, Koffi Alain Attia, Aya Thérèse Ndri-Yoman
    Open Journal of Gastroenterology.2016; 06(02): 39.     CrossRef
  • An Observational, Multicenter, Cohort Study Evaluating the Antiviral Efficacy and Safety in Korean Patients With Chronic Hepatitis B Receiving Pegylated Interferon-alpha 2a (Pegasys)
    Young Eun Chon, Dong Joon Kim, Sang Gyune Kim, In Hee Kim, Si Hyun Bae, Seong Gyu Hwang, Jeong Heo, Jeong Won Jang, Byung Seok Lee, Hyung Joon Kim, Dae Won Jun, Kang Mo Kim, Woo Jin Chung, Moon Seok Choi, Jae Young Jang, Hyung Joon Yim, Won Young Tak, Ki
    Medicine.2016; 95(14): e3026.     CrossRef
  • Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide analogue-naïve and nucleos(t)ide analogue-experienced chronic hepatitis B patients
    Sang Kyung Jung, Kyung-Ah Kim, So Young Ha, Hyun Kyo Lee, Young Doo Kim, Bu Hyun Lee, Woo Hyun Paik, Jong Wook Kim, Won Ki Bae, Nam-Hoon Kim, June Sung Lee, Yoon Jung Jwa
    Clinical and Molecular Hepatology.2015; 21(1): 41.     CrossRef
  • 12,324 View
  • 79 Download
  • 15 Web of Science
  • Crossref
Case Report
A case of isolated metastatic hepatocellular carcinoma arising from the pelvic bone
Kyu Sik Jung, Kyeong Hye Park, Young Eun Chon, Sa Ra Lee, Young Nyun Park, Do Yun Lee, Jin Sil Seong, Jun Yong Park
Korean J Hepatol 2012;18(1):89-93.
Published online March 22, 2012
DOI: https://doi.org/10.3350/kjhep.2012.18.1.89

Reports of metastatic hepatocellular carcinoma (HCC) without a primary liver tumor are rare. Here we present a case of isolated HCC that had metastasized to the pelvic bone without a primary focus. A 73-year-old man presented with severe back and right-leg pain. Radiological examinations, including computed tomography (CT) and magnetic resonance imaging (MRI), revealed a huge mass on the pelvic bone (13×10 cm). He underwent an incisional biopsy, and the results of the subsequent histological examination were consistent with metastatic hepatocellular carcinoma. The tumor cells were positive for cytokeratin (AE1/AE3), hepatocyte paraffin 1, and glypican-3, and negative for CD56, chromogranin A, and synaptophysin on immunohistochemical staining. Examination of the liver by CT, MRI, positron-emission tomography scan, and angiography produced no evidence of a primary tumor. Radiotherapy and transarterial chemoembolization were performed on the pelvic bone, followed by systemic chemotherapy. These combination treatments resulted in tumor regression with necrotic changes. However, multiple lung metastases developed 1 year after the treatment, and the patient was treated with additional systemic chemotherapy.

Citations

Citations to this article as recorded by  Crossref logo
  • A case of complete response to radiotherapy combined with durvalumab and tremelimumab in a patient with unknown primary hepatocellular carcinoma arising in the lumbar spine
    Aiko Tanaka, Tomokazu Kawaoka, Shinsuke Uchikawa, Hatsue Fujino, Atsushi Ono, Eisuke Murakami, Clair Nelson Hayes, Daiki Miki, Masataka Tsuge, Shiro Oka
    Clinical Journal of Gastroenterology.2025; 18(1): 107.     CrossRef
  • Hepatocellular carcinoma presenting as an extrahepatic mass: A case report and review of literature
    Wei Kelly Wu, Krutika Patel, Chandrasekhar Padmanabhan, Kamran Idrees
    World Journal of Gastrointestinal Oncology.2024; 16(5): 2241.     CrossRef
  • Solitary extrahepatic hepatocellular carcinoma in vertebrae without a primary lesion in the liver might originate from bone marrow: a case report and new hypothesis based on a review of the literature and the latest findings
    Yukihiro Shirota, Yoshimichi Ueda, Katsuaki Sato, Yasuhito Takeda, Yuji Hodo, Tokio Wakabayashi
    Clinical Journal of Gastroenterology.2022; 15(6): 1115.     CrossRef
  • Chest Wall Swelling in a Baby Boomer: An Unusual Presentation of Primary Hepatocellular Carcinoma
    Venkata Vinod Kumar Matli, Amina Dhahri, Venkatasai Boda Eswara, Linda D Green
    Cureus.2021;[Epub]     CrossRef
  • Foot and Ankle Hepatocellular Carcinoma Metastasis
    Kalind Parashar, Neeta Pandit-Taskar
    Clinical Nuclear Medicine.2016; 41(1): 69.     CrossRef
  • High dose and compartmental target volume may improve patient outcome after radiotherapy for pelvic bone metastases from hepatocellular carcinoma
    Taehyung Kim, Hye Jung Cha, Jun Won Kim, Jinsil Seong, Ik Jae Lee
    Oncotarget.2016; 7(33): 53921.     CrossRef
  • Hepatocellular Carcinoma with Cervical Spine and Pelvic Bone Metastases Presenting as Unknown Primary Neoplasm
    Seawon Hwang, Jieun Lee, Jung Min Lee, Sook Hee Hong, Myung-Ah Lee, Hoo Geun Chun, Ho Jong Chun, Sung Hak Lee, Eun Sun Jung
    The Korean Journal of Gastroenterology.2015; 66(1): 50.     CrossRef
  • Metastatic hepatocellular carcinoma to the pelvis and vertebrae in a patient with chronic hepatitis ‘C’ with unknown primary
    Syed Hussain Abbas, Muhammad Zia Ul Islam Khan, Muhammad Ijaz, Syed Jawad Akhtar Hussain
    BMJ Case Reports.2015; 2015: bcr2014207249.     CrossRef
  • Using qualitative methods to develop a contextually tailored instrument: Lessons learned
    Haeok Lee, Peter Kiang, Minjin Kim, Semira Semino-Asaro, Mary E Colten, Shirley S Tang, Phala Chea, Sonith Peou, Dorcas C Grigg-Saito
    Asia-Pacific Journal of Oncology Nursing.2015; 2(3): 192.     CrossRef
  • Mediastinal Hepatocellular Carcinoma with Unknown Primary: An Unusual and Rare Presentation
    Peng Soon Koh, Mastura Md Yusof, Boon Koon Yoong, Pathmanathan Rajadurai
    Journal of Gastrointestinal Cancer.2014; 45(S1): 74.     CrossRef
  • 9,329 View
  • 45 Download
  • Crossref
First First Prev Prev
Page of 1
Next Next Last Last
CMH : Clinical and Molecular Hepatology
Twitter